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This work focuses on the development of poly (lactic-co-glycolic acid) (PLGA) 
microsphere/polyvinyl alcohol (PVA) hydrogel composite coatings to permit long-term glucose 
sensor functionality. Two aspects were addressed: 1) prevention of the foreign body reaction 
(FBR) for 6 months; and 2) investigation of the long-term effects of such coatings on glucose 
transport. 
PLGA microspheres were prepared via blending low (RG503H, 25 kDa) and high (DLG7E, 113 
kDa) molecular weight (MW) polymers. “Real-time” in vitro studies demonstrated that the 
dexamethasone release profiles were dependent on the polymer ratios. The duration of drug 
release lasted for approximately 2-6 months with varied burst release and lag phase. A 
discriminatory accelerated in vitro release method was developed to shorten drug release from 6 
months to less than 2 weeks. One formulation exhibited continuous dexamethasone release in 
vitro as well as in vivo efficacy for 4.5 months.  
A central composite design was applied to generate predictive mathematical models of drug 
loading and burst release to facilitate optimization of microsphere composition. The optimized 
composition for long-term drug release with suitable burst release and drug loading was 
DLG7E/RG503H/dexamethasone = 21/4/5 (w/w/w). The optimized microspheres showed 
continuous dexamethasone release in vitro and anti-FBR for 6 months. It was also determined 
that the released dexamethasone was stable for the entire 6-month period. Through analysis of an 
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in vitro drug release heat map together with the in vivo histological data, it was determined that 
the coatings should release approximately 0.1 µg dexamethasone per mg daily in order to counter 
chronic inflammation in rats.  
To evaluate the effect of microsphere degradation in the coatings on glucose transport, two types 
of coatings were prepared incorporating different types of microspheres (i.e. microspheres 
with/without a lag phase). The patterns of pore formation and microsphere swelling were 
evaluated for both coatings. The coating thickness increased as a result of microsphere swelling 
and this was considered to contribute to a decrease in glucose transport. 
In conclusion, the long-term dexamethasone releasing coatings developed here as well as the 
understanding of microsphere degradation within the coatings will facilitate the application of 
such coatings for implantable glucose sensors.
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Chapter 1  
 
Introduction 
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1.1. Background 
Diabetes mellitus is a chronic metabolic disease affecting about 10% of the adult population in the 
U.S. Fluctuation of blood glucose levels is a typical symptom of diabetic patients due to 
underproduction or underutilization of insulin.[1, 2] It is critical for diabetic patients to closely 
monitor their blood glucose levels in order to control disease progression and prevent severe 
complications.[3-6] At present, most diabetic patients rely on glucose strips along with hand held 
glucose meters to measure blood glucose levels via finger pricking.[7, 8] This painful process can 
only measure the glucose concentration for a few time points during a day and is highly user 
dependent. It is easy to miss important fluctuations in glucose using this technique. Continuous 
glucose monitoring provides the advantage of accurately monitoring the blood glucose trend for 
precise calculation of insulin dose therefore eliminating the possibility of hypo/hyperglycemic 
conditions.[9] Currently, commercially available continuous glucose monitoring devices can only 
function for up to 7 days with a glucose oxidase based transcutaneous amperometric sensor.[10] 
This sensor loses functionality after one week due to the foreign body reaction (FBR) which is a 
series of sequential events that ultimately rejects the implanted biomaterials.[11, 12] Initial 
biofouling and sequential inflammatory cell attack can affect enzyme stability and reduce sensor 
sensitivity. Fibrous encapsulation, the final event of FBR, will deprive the sensor from adequate 
analyte supply leading to loss of sensor signal. Inhibition of local FBR is one of the most promising 
strategies to extend sensor lifetime.[13]  
In order to achieve long-term continuous glucose monitoring, a fully implantable glucose 
biosensor is under development by a multi-disciplinary team of UConn scientists. As part of the 
team, our group has developed biocompatible coatings composed of poly (lactic-co-glycolic acid) 
(PLGA) microspheres embedded in a polyvinyl alcohol (PVA) hydrogel for our glucose 
 3 
 
biosensors.[14-17] The PVA hydrogel acts as a hydrophilic base to support the microspheres and 
allows glucose diffusion to the biosensor. PLGA microspheres serve as drug reservoirs to 
continuously release dexamethasone to inhibit local inflammation, therefore, preventing the 
foreign body reaction. However sustained release of dexamethasone is required over the entire 
sensor lifetime since a delayed tissue reaction can develop after exhaustion of the drug.[15] 
Applying the concept of blending different polymers, it is possible to achieve microspheres which 
can sustain dexamethasone release for a longer time period with effective dose. Polymer blends of 
25 KD PLGA and 70 KD PLGA were used to prepare microspheres to sustain the release of 
dexamethasone for approximately 3 months.[18]  
From our previous study, microspheres with approximately 7.6% (w/w) loading, 10 days lag phase 
and 40% (w/w) burst release were able to prevent the FBR for 1 month.[17] Based on the in vivo 
performance of the 1-month formulation, approximately 3 to 6 times the total dose (excluding the 
amount released in the initial burst phase) is required for a 6-month formulation. However, due to 
the limited space in the PVA hydrogel which restricts the maximum amount of microspheres 
embedded, the total dose can be increased by increasing the loading and reducing the burst release 
of dexamethasone in the microspheres. The microsphere formulation can be optimized to achieve 
approximately 15% loading and 10% burst release. The initial burst release is required to inhibit 
the acute inflammatory reaction resulting from sensor implantation. In the case that 10% burst 
release is insufficient, then the dose will be adjusted by loading additional dexamethasone directly 
into the PVA hydrogel. In order to achieve the desired release properties, a quality by design 
approach was used and risk analysis was performed to the microsphere preparation process shown 
in Figure 1.1. As determined from the risk analysis, the most important factor affecting drug release 
is the formulation composition, which is the ratios of drug and the different polymers in the 
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microspheres. The preparation process can also affect drug loading, burst release and the lag phase 
by generating particles with different morphology. However, obtaining a 6-month release 
formulation from a 1-month release formulation, composition adjustment in the polymer blends is 
necessary and should be investigated as a priority. Therefore, the first objective of the current 
research was to develop a dexamethasone loaded PLGA microsphere formulation with 6-month 
continuous drug release using polymer blends by adjusting the formulation composition. 
 
Figure 1.1. Ishikawa diagram for loading, burst release and lag phase of microsphere preparation  
 
Our implantable glucose sensors operate by measuring the electrochemical signal from glucose 
oxidation by glucose oxidase deposited on the surface of the sensor.[19] Sufficient glucose 
diffusion to the glucose oxidase layer is necessary to ensure sensor performance.[20] The presence 
of composite coatings increased sensor response time and reduced sensor sensitivity due to glucose 
diffusion change caused by the coating.[21] Two major factors affecting glucose diffusion through 
the composite coating are the water content in the coating and the inner structure of the 
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composite.[22, 23] Higher water content in the swollen hydrogel can lead to increased diffusion 
coefficient of hydrophilic molecules.[24] Microsphere degradation in the composite coating was 
shown to create macroscopic porosity which can counter biofouling-induced sensor degradation 
for 1 month in vitro.[25] The microsphere degradation was shown to follow a hydration and auto-
catalysis process with a pH gradient from the interior (low pH) to the surface (high pH).[26, 27] 
However, the microscopic structure change (swelling and pore formation) during the degradation 
has not been fully understood. Since porosity and hydrophilicity are the two most important factors 
determining glucose diffusion through the coating, these changes are important for the 
understanding of analyte diffusion through the coating as well as biosensor performance when 
coated. Therefore, the second objective was to investigate the microscopic changes within the 
composite coating to understand its effect on glucose diffusion. 
1.2. Objectives: 
The present research focuses on further optimization of the PLGA microsphere/PVA hydrogel 
composite coating to allow long-term dexamethasone release and sufficient glucose transportation. 
The objectives of the present work include: 1) optimizing PLGA microspheres using polymer 
blends to achieve a formulation suitable for long-term dexamethasone release with 6-month in vivo 
efficacy; and 2) exploring the dynamic changes of composite coatings during microsphere 
degradation which can affect glucose transport. 
The following specific aims were developed to achieve the objectives mentioned above: 
 
Specific Aim 1 (Chapter 2) 
To determine in vitro and in vivo performance of dexamethasone loaded PLGA microspheres 
prepared using polymer blends 
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Specific Aim 2 (Chapter 3) 
To optimize dexamethasone release from PLGA microspheres prepared with polymer blends using 
a design of experiment approach.  
Specific Aim 3 (Chapter 4) 
 
To develop a PLGA microsphere/PVA hydrogel composite coating for glucose sensors to suppress 
the foreign body reaction for 6 months 
Specific Aim 4 (Chapter 5) 
 
To evaluate the effect of PLGA microsphere degradation on glucose transport through composite 
coatings 
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Chapter 2  
In vitro and in vivo performance of dexamethasone loaded PLGA microspheres prepared 
using polymer blends 
  
 10 
 
Abstract 
The foreign body reaction is the major cause of the dysfunction and relatively short lifetime 
associated with implanted glucose biosensors. An effective strategy to maintain sensor 
functionality is to apply biocompatible coatings that elute drug to counter the negative tissue 
reactions. This has been achieved using dexamethasone releasing poly (lactic-co-glycolic acid) 
(PLGA) microspheres embedded in a poly vinyl alcohol (PVA) hydrogel coating. Accordingly, 
the biosensor lifetime relies on the duration and dose of drug release from the coating. To 
achieve long-term drug release mixed populations of microspheres have been used. In the current 
study, microspheres were prepared by blending low (25 KDa) and high (113 KDa) molecular 
weight PLGA at different mass ratios to overcome problems associated with mixing multiple 
populations of microspheres. “Real-time” in vitro studies demonstrated dexamethasone release 
for approximately 5 months. An accelerated method with discriminatory ability was developed to 
shorten drug release to less than 2 weeks. An in vivo pharmacodynamics study demonstrated 
efficacy against the foreign body reaction for 4.5 months. Such composite coatings composed of 
PLGA microspheres prepared using polymer blends could potentially be used to ensure long-
term performance of glucose sensors. 
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2.1. Introduction 
Continuous glucose monitoring (CGM) devices can provide tremendous assistance in the 
management of diabetes through the availability of real-time blood glucose levels [1]. The 
current CGM technology is based on semi-implantable glucose sensors with limited life-time 
(maximum 7 days). Those sensors suffer from instability as a result of the tissue trauma caused 
by implantation and a series of negative tissue responses triggered by the persistent presence of 
the implant [2]. The series of immunological events that include acute inflammation (e.g. 
infiltration of inflammatory cells), chronic inflammation (e.g. activation of fibroblasts), and 
fibrous encapsulation (e.g. collagen capsule formation surrounding the implants) are called the 
foreign body reaction (FBR) [3]. Various approaches have been attempted to overcome the 
foreign body reaction to extend the life-time of glucose sensors. These include application of  
biocompatible coatings [4, 5], release of anti-inflammatory drugs [6-9] as well as delivery of 
angiogenic agents [10, 11]. 
Local delivery of dexamethasone, a potent corticosteroid, has been shown to effectively control 
the FBR in normal rats, diabetic/fatty rats as well as mini pigs [4, 5]. However, delayed tissue 
reaction can develop after exhaustion of the drug [12]. A dexamethasone loaded PLGA 
microsphere/PVA hydrogel coating has been developed to control the FBR for 3 months [9]. 
This was achieved using a mixture of two populations of microspheres, one prepared with low 
Mw PLGA and the other with high Mw PLGA. Dexamethasone release from PLGA 
microspheres typically exhibits a tri-phasic profile with a burst release phase followed by a lag 
phase and a secondary release phase. A long lag phase is usually associated with high Mw PLGA 
based microspheres because the time required for sufficient bulk erosion to allow drug release. 
For example, the lag phase for dexamethasone from the microspheres was extended from 10 
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days to 41 days when the Mw of PLGA was changed from 25 KDa to 70 KDa [13]. The limited 
drug release during the long lag phase of high Mw PLGA microspheres was compensated by 
drug release from the low Mw PLGA microspheres during that period and thus a 3-month 
effective formulation was achieved. Further extending drug release beyond 3 months using this 
strategy would be difficult since this would probably require at least three batches of 
microspheres and the drug release profiles of these batches would need to match one another to 
achieve continuous release with no lag phase. In addition, this would provide challenges in terms 
of processing and product quality control. An alternative strategy is therefore needed to produce 
a single formulation with a short lag phase and long duration of drug release.  
Drug release from PLGA microspheres is controlled by polymer degradation, which is a result of 
the polymer backbone hydrolyzing into oligomers and monomers. Bulk erosion of the PLGA 
polymer matrix usually occurs from water penetration followed by autocatalysis of the ester 
bonds. The long lag phase associated with the degradation of high Mw PLGAs is a result of the 
relatively slow water penetration into these polymers due to their increased hydrophobicity 
compared to low Mw PLGAs. This can be shortened by enhancing the hydrophilicity of the 
polymer using approaches such as decreasing polymer Mw and introducing hydrophilic groups. 
Blending low Mw PLGA with high Mw PLGA is an intriguing prospect since the low Mw 
PLGA may facilitate degradation of the high Mw PLGA via increased water absorption and 
generation of acidic oligomers that will result in autocatalysis of the polymer matrix. A design of 
experiment (DoE) approach was used to generate a design space to optimize drug release profiles 
of PLGA microspheres prepared using polymer blends.[14] Sustained dexamethasone release for 
approximately 3 months in vitro was achieved by blending 25 KDa PLGA with 70 KDa PLGA 
[13].  
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Drug release profiles are important product performance indicators. Since real-time release 
testing of the target product would last for months, it is essential to develop accelerated release 
testing methods for quality control purposes. Accelerated release testing for microsphere 
products can be achieved by changing various release conditions (such as pH, temperature, 
organic solvent, and surfactant). For example adjusting the media to acidic pH conditions has 
been shown to expedite drug release as PLGA degradation is catalyzed under acidic conditions 
[15].However the drug release mechanism was shown to change from bulk erosion to surface 
erosion when lower pH condition were used. Elevating temperature can facilitate drug diffusion 
from the microspheres as well as expedite polymer matrix degradation. It has been shown that 
accelerated drug release from PLGA microspheres can be achieved under elevated temperature 
conditions [16-18].  
In the current study, the in vitro and in vivo performance of microspheres prepared by blending 
low (25 KDa) and high (113 KDa) Mw PLGA was investigated. The microspheres were 
prepared with different polymer mass ratios and characterized for physicochemical properties 
such as particle size, glass transition temperatures and morphology. “Real-time” and accelerated 
release testing was performed. The accelerated release method was able to shorten the duration 
of drug release while maintaining discriminatory ability. The “Real-time” release profiles 
provided guidance for formulation screening towards in vivo testing. The selected formulation 
was evaluated in vivo and histological results demonstrated that the foreign body reaction was 
inhibited for at least 4.5 months.  
2.2. Material and Methods 
2.2.1. Materials 
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Dexamethasone was purchased from Cayman Chemical (Ann Arbor, MI), poly (vinyl alcohol) 
(PVA, Mw 30–70 KD), sodium chloride (NaCl, ACS grade), sodium azide (NaN3), sodium 
phosphate dibasic dihydrate (Na2HPO4·2H2O), sodium phosphate monobasic (NaH2PO4) and 
dimethyl sulfoxide (DMSO) were purchased from Sigma–Aldrich (St. Louis, MO). PVA (99% 
hydrolyzed, Mw 133 KD) was purchased from Polysciences, Inc. (Warrington, PA). PLGA 
Resomer® RG503H 5050 (RG503H, inherent viscosity 0.32–0.44 dl/g) was a gift from 
Boehringer-Ingelheim. PLGA 9010 DLG7E (DLG7E, inherent viscosity 0.6-0.8 dL/g) was 
purchased from Lakeshore Biomaterials (Birmingham, AL). RG503H has carboxylic acid end 
groups and DLG7E is end-capped with a lauryl ester group. Methylene chloride (DCM), 
acetonitrile (ACN, HPLC grade), and tetrahydrofuran (THF, HPLC grade) were purchased from 
Fisher Scientific (Pittsburgh, PA). NanopureTM quality water (Barnstead, Dubuque, IA) was 
used for all studies. 
2.2.2.  Methods 
2.2.2.1. Preparation of microspheres and composite coated implants 
Dexamethasone loaded microsphere formulations were prepared using an oil-in-water (o/w) 
emulsion solvent extraction/evaporation technique according to the compositions listed in Table 
2.1. The PLGA polymer was dissolved in 2 ml of methylene chloride and dexamethasone was 
dispersed in this solution. Following 20-minute sonication in a bath sonicator, the dispersion was 
further dispersed using a T 25 digital ULTRA-TURRAX homogenizer (IKA Works, Inc., 
Wilmington, NC) at 10,000 rpm for 1 min. In order to form an emulsion, the organic phase was 
homogenized into a 10-ml PVA solution (1% (w/v), average Mw 30–70 KDa) at 10,000 rpm for 
2.5 min. The emulsion was then transferred into a 125 ml aqueous PVA solution (0.1% (w/v), 
Mw 30-70 KDa) and stirred at 600 rpm under vacuum. After 2.5 hours, hardened microspheres 
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were transferred to 50 mL centrifuge tubes and collected through centrifugation under 1500 rpm 
for 2 minutes. The microspheres were then washed three times with deionized water (10 mL each 
time), recollected using the same centrifugation procedure and dried via freeze drying. The 
prepared microspheres were stored at 4°C until further use. Blank microspheres were prepared 
following the same procedure except that dexamethasone was not added. 
Cylindrical implants were prepared using a two-piece grooved mold based method after three 
freeze-thaw cycles [19]. Briefly, 150 mg of microspheres (F-3 in Table 2.1) was suspended using 
1 ml of 5% w/w PVA solution (133 KDa) and filled in a 1-mL syringe. The PVA solution was 
pre-filtrated using 0.22-µm sterile filters to ensure sterility. The suspension was sonicated in a 
bath sonicator for 10 seconds followed by one freeze–thaw cycle (2 hour at - 20 °C and 1 hour at 
ambient temperature). The partially thickened suspension was fed into a 2-piece mold with 1.5-
mm grooves. The dummy sensors (silicon chips with dimension of 5 × 0.5 × 0.5 mm) were 
sandwiched between the two mold pieces and were then subjected to additional two freeze thaw 
cycles. The coated dummy sensors were air dried and cut into 7-mm length implants. The 
grooves in the mold are 1.5-mm diameter. To ensure size consistency of each implant, dummy 
sensors are placed in the center of the groove between the two pieces of the mold. Sterile tools 
(e.g. vials, tubes, twizzles and containers, etc.) were used in the coating process. All the 
procedures were conducted in a laminar flow hood under sterile conditions. Blank formulations 
were also prepared using blank PLGA microspheres without dexamethasone.  
2.2.3. In vitro characterization of microspheres and composite coatings  
2.2.3.1. Drug loading 
Approximately 5 mg of dexamethasone-loaded PLGA microspheres was dissolved in 10 ml THF 
for drug loading determination. A previously reported HPLC method was used for analysis of 
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dexamethasone concentration for the loading calculation [14]. Briefly, the solution was filtered 
(Millex® HV, PVDF 0.45 μm syringe filter) and subjected to HPLC analysis with 5 μl of 
injection volume. A Perkin Elmer series 200 HPLC system (Shelton, CT) was equipped with a 
UV absorbance detector (240 nm wave length for dexamethasone analysis). 
Acetonitrile/water/phosphoric acid (35/70/0.5, v/v/v) was used as the mobile phase. A Zobax 
C18 (4.6 mm × 15 cm, Agilent, Santa Clara, CA) analytical column was used with a flow rate of 
1 ml/min. The chromatographs were analyzed by PeakSimple™ Chromatography System (SRI 
instruments, Torrance, CA).   
Drug loading was determined as: % drug loading = (weight of drug loaded/weight of 
microspheres) × 100%.  
2.2.3.2. Microsphere characterization 
The particle size and size distribution was determined using an AccuSizer 780A autodiluter 
particle sizing system (Nicomp, Santa Barbara, CA). Approximately 5 mg of microspheres were 
dispersed in 1 ml of 0.1% (w/v) PVA solution (30-70 KDa) and 100 μl of the dispersion was 
injected into the system for particle size analysis. All measurements were conducted in triplicate. 
A TA Q1000 differential scanning calorimeter (DSC) (TA, New Castle, DE) was used to 
determine the glass transition temperature (Tg) of the prepared microspheres. Modulated DSC 
was performed with the cycle below: the samples were heated at a rate of 3 °C/min from 4°C to 
80 °C at a modulating oscillatory frequency of 1°C/min. The thermograms were analyzed using 
Universal Analysis software (TA Instruments) to determine the glass transition temperature. 
The morphology of the microspheres were determined using a scanning electron microscopy (a 
JEOL JSM-6335F unit). Samples were mounted on carbon taped aluminum stubs and sputter 
coated with gold for 1.5 min at 6 mA before imaging. 
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2.2.3.3. In vitro release testing  
In vitro release testing was performed on the PLGA microsphere/PVA hydrogel (99% 
hydrolyzed, Mw 133 KD) composites since the purpose was to test the performance of the 
coatings rather than the microspheres alone. The composites were prepared using a freeze-thaw 
method described previously [13]. Briefly, approximately 75 mg of PLGA microspheres were 
dispersed into the PVA hydrogel (5% w/v) solution, then this suspension was filled into a pre-
made mold (15×38×2 mm) and subjected to three freeze-thaw cycles consisting of 2 h freezing at 
−20°C followed by 1 h thawing at room temperature to form a physically crosslinked hydrogel 
resulting from PVA crystallization. The composites were then air dried. Approximately 8 mg 
composite samples were immersed in 5 ml of 10 mM PBS (pH 7.4) with 0.1% NaN3 and 
incubated at both elevated temperature (45 and 53 °C) and body temperature (37 °C) under 
constant agitation. At pre-determined time points, all the release media was removed and 
replenished with the same volume of fresh media. Sink conditions were maintained throughout. 
The samples were filtrated through 0.45 μm syringe filters and the concentration of 
dexamethasone in each sample was determined using the HPLC method as described above. The 
release profiles were plotted as cumulative % release vs. time. Cumulative percent release at a 
given time point was calculated as: cumulative percent release = (total amount released at 
sampling time/total amount loaded) × 100. The values are reported as mean ± standard deviation 
(n = 3). 
2.2.4. In vivo pharmacodynamics study of composite coated dummy sensors 
PLGA/PVA composite coated dummy sensors prepared in section 2.2.1.2 were implanted into 
the interscapular subcutaneous tissue of male Sprague-Dawley rats (weighing ~ 200 g, n=3) 
using 16-gauge thin wall needles. During the implantation procedure, the rats were under 
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anesthesia using 2% isoflurane in oxygen. Before implantation, the back of each animal was 
shaved and wiped with betadine solution. All of the procedures were conducted under aseptic 
conditions. One composite was implanted per rat on days 0, 35, 151 and 162 and the rats were 
sacrificed at day 165. Three rats were used for one group and each rat had a total of 4 composite 
implants at the end of the study. Accordingly, the duration of implantation for each of these 
implants is 165, 130, 14, and 3 days, respectively. The implants with surrounding subcutaneous 
tissue were harvested and fixed in 10% buffered formalin solution (Sigma-Aldrich Co. LLC.). 
All animal studies were reviewed and approved by the Institutional Animal Care and Use 
Committee (IACUC) within the University of Connecticut prior to beginning the experiments. 
Paraffin blocks were prepared for tissue sections and a blinded histological evaluation was 
performed following hematoxylin and eosin (H&E) staining. Tissue samples were observed and 
digitally stored using an Olympus microscope (model BX51, Olympus America, Melville, NY). 
2.3. Results and Discussion 
2.3.1. In vitro characterization of microspheres 
The microspheres were characterized for drug loading, particle size and thermal properties 
(Table 2.1). No significant differences were observed in the average particle size of all 
formulations investigated. For F-1, F-2 and F-3, the drug loading was approximately 8% (w/w) 
with a slight increase in loading with increase in the ratio of the more hydrophobic DLG7E 
polymer in the formulation. The drug loading of the F-4 formulation was significantly lower than 
that of the other formulations as determined by the paired student T-test (p<0.05 as significant).  
This increase hydrophobicity results in faster polymer solidification and therefore drug 
encapsulation may be enhanced. The glass transition temperatures for microspheres prepared 
with polymer blends are between the glass transition temperatures of DLG7E (52.97 °C) and 
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RG503H (42.1 °C). Although the rank order for the Tg(s) is consistent with the empirical Tg(s) 
calculated from Fox Equation for polymer blends [20], polymer segregation is still possible 
considering that the Tg(s) of the two polymers are very close. SEM examination will provide 
more detailed information regarding microsphere morphology. SEM micrographs (Figure 2.1) 
showed spherical microspheres with smooth morphology for most of the particles except for 
those of F-4. Large pores and crevasses were observed for the F-4 microspheres which can be 
explained by possible polymer phase separation in this formulation considering that equal 
amounts of the low and high Mw polymers were added in F-4. The peculiar structure of the F-4 
formulation is an indication of phase separation. In addition, much higher burst release was 
observed for the F-4 formulation when compared to the other formulations.  
2.3.2. “Real-time” in vitro drug release from composites 
The release profiles obtained for the microsphere formulations under “real-time” conditions (37 
˚C) are shown in Figure 2.2 Dexamethasone release from PLGA microspheres typically has an 
initial burst phase, followed by a lag phase and then a secondary zero-order release phase. These 
three distinct phases were identified for all the formulations. The F-4 formulation exhibited the 
highest burst release (approximately 35%) and the shortest lag phase (approximately 10 days). 
The pores and crevasses observed in the surface of F-4 formulation (Figure 2.1.) are considered 
to be responsible for the high burst release associated with this formulation since easier drug 
diffusion from the surface is expected. The release of dexamethasone from the F-4 formulation 
reached a plateau within 1.5 months. Microspheres prepared using 100% RG503H have 
previously been shown to have a burst release of approximately 40% and a lag phase of 
approximately 7 days and the release was complete within 35 days. [18] The release profile of 
the F-4 formulation is closer to that of the microspheres prepared with 100% RG503H compared 
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to the other two polymer blend microspheres (F-2 and F-3). This may be a result of polymer 
phase separation in this microsphere formulation, as discussed above, as well as the relatively 
higher hydrophilicity of this formulation increasing water uptake and consequent polymer 
degradation. The F-1 formulation (prepared with 100% of the high Mw DLG7E polymer) has the 
lowest burst release (approximately 8%), the longest lag phase (approximately 4 months) and the 
entire release profile lasts for approximately 7 months. The DLG7E polymer has high 
hydrophobicity due to its high Mw and high lactic:glycolic acid ratio (90:10). Accordingly, 
polymer degradation is significantly slower compared to microspheres prepared with the 
polymer blends as the rate of water penetration and subsequent polymer hydrolysis are 
significantly reduced. The long lag phase of the F-1 formulation prohibits its use for the purpose 
of continuous drug release. The drug release profiles of the F-2 and F-3 formulations are in 
between those of the F-1 and F-4 formulations. These formulations have burst release phases of 
approximately 15%, lag phases of less than 2 weeks and their entire release profiles last for 
approximately 4.5 months. Water penetration and hence polymer degradation is more rapid 
compared to the F-1 formulation, since these two formulations were prepared by blending the 
more hydrophilic RG503H polymer with the DLG7E polymer. The relatively high hydrophilicity 
of the RG503H is attributed to three factors: 1) a relatively small Mw of ~25 KDa; 2) a 
lactic/glycolic acid ratio of 50/50; and 3) the fact that it is capped with hydrophilic carboxylic 
groups [21]. In the blended polymers, the low Mw RG503H facilitates water penetration and the 
subsequent degradation of the RG503H polymer generates lactic/glycolic acid oligomers and 
monomers. The resultant decrease in pH catalyzes the degradation of the high Mw polymer 
(DLG7E). Therefore, the long lag phase associated with the high Mw polymer is eliminated and 
the microspheres prepared with polymer blends exhibit continuous release profiles following a 
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small burst and a short lag phase. Although the release profiles of the F-2 and F-3 formulations 
were similar, the F-3 formulation was selected for further studies. 
2.3.3. Accelerated in vitro drug release from composites 
Drug release profiles are important product performance indicators. A real-time release profile is 
typically a good indication for the in vivo performance of the formulation. Considering that real-
time release tests for microsphere products can last for months, it is essential to develop 
accelerated release testing methods for quality control purposes. Maintaining the discriminatory 
ability of the method while shortening the testing duration is essential. Accelerated release tests 
can be conducted by adjusting parameters such as temperature, solvent, ionic strength, pH, and 
agitation rate as well as addition of enzymes and surfactants.[22] It has been shown that 
elevating temperature is an effective method of accelerating drug release from PLGA 
microsphere/PVA hydrogel composites [16, 18]. 
The F-1, F-3 and F-4 formulations were tested under elevated temperature conditions. Figure 
2.3-A and B shows the release profiles for the three formulations at 45 ˚C and 53 ˚C, 
respectively. In order to investigate the effect of the glass transition temperature on the drug 
release profiles, two temperatures (one higher and another lower than the Tg of the formulations) 
were chosen for accelerated release testing method development. The release profiles for the 
individual formulations at real time (37 ˚C) as well as accelerated (45 and 53 ˚C) conditions are 
plotted in Figure 2.3-C, D and E for direct comparison. At 45 °C, although there were no lag 
phases, three distinct drug release phases were observed for all formulations. The burst release 
for F-1 and 3 is close to 10%, which is similar to that obtained at 37 °C. A slightly higher burst 
release was observed for the F-4 formulation with approximately 45% released after 24 hours 
compared to 35% at 37 °C. The middle phases for the F-3 and F-4 formulations at 45 °C lasted 
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for approximately 5 days and this can be compared to their lag phases at 37 °C which lasted for 
approximately 3 weeks. The middle phase for the F-1 formulation lasted approximately 1 month, 
which can be compared to the 4-month lag phase observed at 37 °C. It is speculated that the drug 
diffusion plays a significant role in the middle phase at 45 ˚C, while the third phase is both 
diffusion and erosion controlled. At 53 °C, drug release from all formulations was further 
accelerated and the typical three phase release profile was lost. Instead, formulations F-3 and F-4 
showed two distinct release phases and the release was complete in less than 1 week. 
Formulation F-1 also showed two release phases with a slight inflection point around day 5 and 
release from this formulation was complete in less than 2 weeks. The glass transition 
temperatures of the F-1, F-3 and F-4 formulations are below 53 °C (51.31 °C, 50.25°C, and 
48.06°C, respectively). In addition to acceleration of polymer degradation, polymer chain 
mobility increases greatly at temperatures above the Tg which facilitates drug diffusion from the 
polymer matrix. Both of these factors contribute to change in the drug release mechanism and 
hence the changes observed in the release profiles of all three formulations. Nevertheless, the 
accelerated tests at both 45 and 53 °C were able to distinguish the three formulations. Drug 
release testing performed at 53 °C may be more suitable for quality assurance purposes due to 
the significant reduction in the duration of release testing.   
2.3.4. In vivo pharmacodynamics  
From the in vitro release tests the F-3 formulation was selected as the most promising 
formulation to achieve long-term continuous dexamethasone release in vivo. The F-1 formulation 
is unsuitable due to the extremely long lag phase (5 months). The F-4 formulation is unsuitable 
due to the short duration of drug release (1.5 months). The F-3 formulation is superior to the F-2 
formulation since it has a slightly higher daily dose. The F-3 formulation was able to control the 
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foreign body reaction for 4.5 months while the blank formulations triggered both acute and 
chronic inflammation. (Figure 2.4) The control group exhibited different stages of the foreign 
body reaction: 1) inflammatory cell recruitment (mostly neutrophils as indicated by the red 
arrows) at day 3; 2) fibroblast activation and alignment at day 14 (indicated by green arrows); 
and 3) fibrous encapsulation (indicated by yellow arrows) at 4.5 and 5.5 months. The composites 
prepared using the F-3 formulation were able to prevent both acute inflammation (no 
inflammatory cell accumulation at day 3) and chronic inflammation (no activated fibroblast or 
formation of fibrous encapsulation) up to 4.5 months. At 5.5 months post implantation, fibrous 
encapsulation was observed for the F-3 formulation composites indicating that dexamethasone 
was depleted or was released at an insufficient dose at this point. The in vivo performance of the 
F-3 formulation is therefore consistent with its in vitro release profile. This continuously 
releasing (4.5-month) formulation has the longest duration of action of any dexamethasone 
microsphere formulation reported thus far. An even longer duration of action (approximately 7 
months) could be achieved using a mixture of the F-1 and F-3 formulations.  
2.4. Conclusions 
The current study established the concept of blending different PLGA polymers to achieve 
continuous and long-term drug release from PLGA microspheres by integrating the benefits of 
both small and high Mw polymers. The low Mw PLGA increases water absorption into the 
polymer matrix and generates acidic oligomers/monomers which facilitates the autocatalysis of 
the high Mw polymer resulting in a smoother release profile. A polymer blend based 
dexamethasone microsphere/hydrogel formulation with continuous drug release and in vivo 
efficacy of 4.5 months was achieved. This formulation has the longest duration of action among 
any reported dexamethasone microsphere formulations thus far. In addition, it may be possible to 
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further extend the duration of action in vivo to approximately 7 months by mixing two of the 
microsphere formulations reported here. The composition of the polymer blends is critical to the 
release profile. One formulation blending the low and high Mw polymer at a 50:50 ratio 
exhibited high burst and short duration of drug release due to polymer phase separation during 
the microsphere formation process. In addition, accelerated drug release methods were 
developed under elevated temperature conditions to significantly shorten the testing period from 
months to days while retaining the ability to discriminate among the various formulations. The 
successful development of a long-term effective composite coating paves the way for the 
realization of long-term, totally implantable continuous glucose monitoring systems. 
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2.5. Tables and Figures 
Table 2.1. Composition and physical characteristics of microsphere formulations using polymer 
blends 
Formu
lation 
Dexame
thasone 
(mg) 
PLGA 
(DLG7
E, mg) 
PLGA 
(RG503
H, mg) 
Drug 
Loading 
(w/w) 
Particle Size 
(by number, 
µm) 
 
Tg 
(°C) 
F-1 50 500 - 8.34 ± 0.27 5.38 ± 5.27 51.3 
F-2 50 375 125 8.09 ± 0.07 4.78 ± 4.62 51.3 
F-3 50 333 167 8.11 ± 0.11 5.08 ± 4.88 50.3 
F-4 50 250 250 7.86 ± 0.04 4.43 ± 4.42 48.1 
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Figure 2.1. Scanning electron micrographs of microsphere formulations prepared using blends 
of PLGA polymers at various mass ratios: DLG7E/RG503H (w/w)=1/0, 3/1, 2/1 and 1/1 for F-1 
(A), F-2 (B), F-3 (C) and F-4 (D), respectively. 
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Figure 2.2. In vitro release profiles of microsphere/PVA hydrogel composite formulations at 37 
°C. The cumulative % release was plotted as mean ± SD (n=3). Different ratios of polymers were 
used to prepare the microspheres: DLG7E/RG503H (w/w) = 1/0, 3/1, 2/1 and 1/1 for F-1, F-2, F-
3 and F-4, respectively.  
 
 28 
 
 
Figure 2.3. In vitro release profiles of microsphere formulations at elevated temperatures of 45 
°C (A) and 53 °C (B). Different ratios of polymers were used to prepare the microspheres: 
DLG7E/RG503H (w/w) = 1/0, 2/1, and 1/1 for F-1, F-3 and F-4, respectively. In vitro release 
profiles of microsphere formulations at both “real-time” and elevated temperatures (45 °C and 53 
°C) of the F-1 (C), F-3 (D) and F-4 (E) formulations. 
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Figure 2.4. In vivo pharmacodynamics of implanted composite coated dummy sensors in rats. 
Stars indicate where the implants were located, the red arrows indicate inflammatory cell 
infiltration during the acute inflammatory phase, the green arrow indicates activated fibroblasts 
present during the transitional phase from acute to chronic inflammation, and the yellow arrows 
indicate a fibrous capsule formed around the implants. 
 
 
  
 30 
 
2.6. References 
1. Vaddiraju, S., et al., Technologies for Continuous Glucose Monitoring: Current Problems and 
Future Promises. Journal of Diabetes Science and Technology, 2010. 4(6): p. 1540-1562. 
2. Morais, J., F. Papadimitrakopoulos, and D. Burgess, Biomaterials/Tissue Interactions: Possible 
Solutions to Overcome Foreign Body Response. The AAPS Journal, 2010. 12(2): p. 188-196. 
3. Anderson, J.M., A. Rodriguez, and D.T. Chang, FOREIGN BODY REACTION TO 
BIOMATERIALS. Seminars in immunology, 2008. 20(2): p. 86-100. 
4. Wang, Y., F. Papadimitrakopoulos, and D.J. Burgess, Polymeric “smart” coatings to prevent 
foreign body response to implantable biosensors. Journal of Controlled Release, 2013. 169(3): p. 
341-347. 
5. Kastellorizios, M., F. Papadimitrakopoulos, and D.J. Burgess, Prevention of foreign body 
reaction in a pre-clinical large animal model. J Control Release, 2015. 202: p. 101-7. 
6. Patil, S.D., F. Papadimitrakopoulos, and D.J. Burgess, Dexamethasone-loaded poly(lactic-co-
glycolic) acid microspheres/poly(vinyl alcohol) hydrogel composite coatings for inflammation 
control. Diabetes Technol Ther, 2004. 6(6): p. 887-97. 
7. Galeska, I., et al., Controlled release of dexamethasone from PLGA microspheres embedded 
within polyacid-containing PVA hydrogels. The AAPS Journal, 2005. 7(1): p. E231-E240. 
8. Zolnik, B.S. and D.J. Burgess, Evaluation of in vivo–in vitro release of dexamethasone from 
PLGA microspheres. Journal of Controlled Release, 2008. 127(2): p. 137-145. 
9. Bhardwaj, U., et al., PLGA/PVA hydrogel composites for long-term inflammation control 
following s.c. implantation. International Journal of Pharmaceutics, 2010. 384(1–2): p. 78-86. 
10. Patil, S.D., F. Papadmitrakopoulos, and D.J. Burgess, Concurrent delivery of dexamethasone and 
VEGF for localized inflammation control and angiogenesis. Journal of Controlled Release, 2007. 
117(1): p. 68-79. 
11. Laschke, M.W., et al., Locally applied macrophage-activating lipopeptide-2 (MALP-2) promotes 
early vascularization of implanted porous polyethylene (Medpor(R)). Acta Biomater, 2014. 
10(11): p. 4661-9. 
12. Bhardwaj, U., et al., Controlling Acute Inflammation with Fast Releasing Dexamethasone-PLGA 
Microsphere/PVA Hydrogel Composites for Implantable Devices. Journal of Diabetes Science 
and Technology, 2007. 1(1): p. 8-17. 
13. Wang, Y., B. Gu, and D. Burgess, Microspheres Prepared with PLGA Blends for Delivery of 
Dexamethasone for Implantable Medical Devices. Pharmaceutical Research, 2014. 31(2): p. 373-
381. 
14. Gu, B. and D.J. Burgess, Prediction of dexamethasone release from PLGA microspheres 
prepared with polymer blends using a design of experiment approach. International Journal of 
Pharmaceutics. 
15. Zolnik, B.S. and D.J. Burgess, Effect of acidic pH on PLGA microsphere degradation and 
release. Journal of Controlled Release, 2007. 122(3): p. 338-344. 
16. Zolnik, B.S., P.E. Leary, and D.J. Burgess, Elevated temperature accelerated release testing of 
PLGA microspheres. Journal of Controlled Release, 2006. 112(3): p. 293-300. 
17. Rawat, A., U. Bhardwaj, and D.J. Burgess, Comparison of in vitro–in vivo release of Risperdal® 
Consta® microspheres. International Journal of Pharmaceutics, 2012. 434(1–2): p. 115-121. 
18. Shen, J. and D.J. Burgess, Accelerated in vitro release testing of implantable PLGA 
microsphere/PVA hydrogel composite coatings. International Journal of Pharmaceutics, 2012. 
422(1–2): p. 341-348. 
19. Kastellorizios, M., F. Papadimitrakopoulos, and D.J. Burgess, Prevention of foreign body 
reaction in a pre-clinical large animal model. Journal of Controlled Release, 2015. 202(0): p. 
101-107. 
20. Hiemenz, P.T.L., ed. Polymer Chemistry. 2007, CRC Press: Boca Raton, Florida. 
 31 
 
21. Makadia, H.K. and S.J. Siegel, Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable 
Controlled Drug Delivery Carrier. Polymers (Basel), 2011. 3(3): p. 1377-1397. 
22. Burgess, D.J., et al., Assuring quality and performance of sustained and controlled release 
parenterals: EUFEPS workshop report. The AAPS Journal, 2004. 6(1): p. 100-11. 
 32 
 
 
Chapter 3 
Optimization of dexamethasone release from PLGA microspheres prepared 
with polymer blends using a design of experiment approach 
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Abstract 
Hydrophobic drug release from poly (lactic-co-glycolic acid) (PLGA) microspheres typically 
exhibits a tri-phasic profile with a burst release phase followed by a lag phase and a secondary 
release phase. High burst release can be associated with adverse effects and the efficacy of the 
formulation cannot be ensured during a long lag phase. Accordingly, the development of a long-
acting microsphere product requires optimization of all drug release phases. The purpose of the 
current study was to investigate whether a blend of low and high molecular weight polymers can 
be used to reduce the burst release and eliminate/minimize the lag phase. A single emulsion 
solvent evaporation method was used to prepare microspheres using blends of two PLGA 
polymers (PLGA5050 (25KDa) and PLGA9010 (113KDa)). A central composite design 
approach was applied to investigate the effect of formulation composition on dexamethasone 
release from these microspheres. Mathematical models obtained from this design of experiments 
study were utilized to generate a design space with maximized microsphere drug loading and 
reduced burst release. Specifically, a drug loading close to 15% can be achieved and a burst 
release less than 10% when a composition of 80% PLGA9010 and 90 mg of dexamethasone is 
used. In order to better describe the lag phase, a heat map was generated based on 
dexamethasone release from the PLGA microsphere/PVA hydrogel composite coatings. Using 
the heat map an optimized formulation with minimum lag phase was selected. The microspheres 
were also characterized for particle size/size distribution, thermal properties and morphology. 
The particle size was demonstrated to be related to the polymer concentration and the ratio of the 
two polymers but not to the dexamethasone concentration.   
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3.1 Introduction 
Diabetes mellitus is a chronic metabolic disease affecting about 387 million people globally (2014 
data) according to International Diabetes Federation [1]. Fluctuations in blood glucose levels is a 
typical symptom of diabetic patients due to underproduction or underutilization of insulin. It is 
critical for diabetic patients to closely monitor their blood glucose levels in order to control disease 
progression and prevent severe complications [2]. At present, most diabetic patients rely on 
glucose strips along with hand held glucose meters to measure blood glucose levels via finger 
pricking [3]. Continuous glucose monitoring provides the advantage of accurately monitoring the 
blood glucose trend for precise calculation of the insulin dose, therefore eliminating the possibility 
of hypo/hyperglycemic conditions [4]. Currently, commercially available continuous glucose 
monitoring devices can only function for up to 7 days with a glucose oxidase based transcutaneous 
amperometric sensor [5]. These sensors lose functionality after one week due to the foreign body 
reaction (FBR) which is a series of sequential events that ultimately rejects the implanted 
biomaterials [6]. The initial biofouling and sequential inflammatory cell attack can affect enzyme 
stability and reduce sensor sensitivity. Fibrous encapsulation, the final event of FBR, deprives the 
sensor of adequate analyte supply leading to a loss in sensor signal. Inhibition of local FBR is one 
of the most promising strategies to extend sensor lifetime [7].  
In order to achieve long-term continuous glucose monitoring, biocompatible coatings composed 
of poly (lactic-co-glycolic acid) (PLGA) microspheres embedded in a polyvinyl alcohol (PVA) 
hydrogel have been developed [8-12] for a totally implantable, miniaturized (0.5mm x 0.5 mm x 
5 mm) glucose biosensor (being developed in our laboratory). The PVA hydrogel acts as a 
hydrophilic base to support the microspheres and to allow glucose to readily diffuse to the 
biosensor. PLGA microspheres serve as drug reservoirs to continuously release dexamethasone to 
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inhibit local inflammation, therefore, preventing the foreign body reaction. However sustained 
release of dexamethasone is required over the entire sensor lifetime since a delayed tissue reaction 
can develop after exhaustion of the drug [9].  
Dexamethasone loaded microspheres tend to have an initial burst phase, followed by a lag phase 
and then a secondary release phase [13]. A sufficient amount of dexamethasone should be released 
during the burst release phase to inhibit the acute inflammation that is caused by the trauma of 
implantation. However, too high an initial burst release may cause dose dumping, which can lead 
to severe side effects. High drug loading is desired as this can benefit both the daily dose and the 
duration of drug release. The lag phase, where the daily drug release is typically low, should be as 
short as possible in order to ensure efficacy during that period. It has always been a challenge to 
control the burst release and increase drug loading for PLGA based microspheres [14]. The burst 
release of drug from microspheres can be adjusted through process controls such as stabilizing the 
primary emulsion and changing the solvent evaporation rate by modifying the agitation type/speed 
[15]. The use of co-solvents is another effective strategy to reduce the initial burst release. For 
example, burst release of 10-hydroxycampetothecin from PLGA microspheres was reduced when 
dimethylformadide was used as a co-solvent with methylene chloride{Shenderova, 1997 #25}. 
However, there has been a paucity of literature reports on how to control/eliminate the microsphere 
lag phase. Changing the composition of the formulation is the most straightforward and effective 
way to adjust microsphere release properties. Applying the concept of blending different polymers, 
it is possible to adjust the dexamethasone release profile by decreasing the burst release and 
shortening the lag phase to achieve sustained drug release for approximately 3 months [16]. For 
ganciclovir microspheres prepared by blending PLGA7525 and Resomer RG 502H, drug 
encapsulation and release parameters were shown to be altered significantly [17]. Modified 
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leuprolide release from PLGA microspheres was also reported by blending 8.6 KDa and 28.3 KDa 
polymers [18].  
Based on the in vivo performance of previous formulations, further formulation optimization to 
increase the drug loading and control the burst release and lag phase is required to establish a 
long-term (6-month) effective microsphere formulation [11, 19]. Quality by design (QbD) and 
design of experiment (DoE) approaches have been widely used in the development of various 
pharmaceutical formulations [20-22]. Mathematical models generated from DoE studies can also 
be used for response prediction and formulation optimization purposes [23, 24]. In the current 
study, the drug loading and initial release phase of the dexamethasone microspheres were 
optimized using a DoE approach. In addition to burst release, the lag phase of the PLGA 
microspheres was also adjusted to achieve sufficient theoretical daily dose (0.17 µg/day from our 
previous study[19]) for in vivo efficacy. The release characteristics were correlated with the 
physico-chemical properties of the PLGA microspheres such as thermal properties, particle size 
as well as morphology.  
3.2 Material and Methods 
3.2.1 Materials 
Dexamethasone was purchased from Cayman Chemical (Ann Arbor, MI), poly (vinyl alcohol) 
(PVA, Mw 30–70 KD), sodium chloride (NaCl, ACS grade), sodium azide (NaN3), sodium 
phosphate dibasic dihydrate (Na2HPO4·2H2O), sodium phosphate monobasic (NaH2PO4) and 
dimethyl sulfoxide (DMSO) were purchased from Sigma–Aldrich (St. Louis, MO). PVA (99% 
hydrolyzed, Mw 133 KD) was purchased from Polysciences, Inc. (Warrington, PA). PLGA 
Resomer® RG503H 5050 (RG503H, inherent viscosity 0.32–0.44 dl/g) was a gift from 
Boehringer-Ingelheim. PLGA 9010 DLG7E (DLG7E, inherent viscosity 0.6-0.8 dL/g) was 
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purchased from Lakeshore Biomaterials (Birmingham, AL). RG503H has carboxylic acid end 
groups and DLG7E is end-capped with a lauryl ester group. Methylene chloride (DCM), 
acetonitrile (ACN, HPLC grade), and tetrahydrofuran (THF, HPLC grade) were purchased from 
Fisher Scientific (Pittsburgh, PA). NanopureTM quality water (Barnstead, Dubuque, IA) was 
used for all studies. 
3.2.2 Methods 
3.2.2.1 Preparation of microspheres 
Dexamethasone loaded microsphere formulations were prepared using an oil-in-water (o/w) 
emulsion solvent extraction/evaporation technique. The PLGA polymers (amounts and ratios as 
indicated in Table 3.1) were dissolved in 2 ml of methylene chloride and dexamethasone 
(amounts as indicated in Table 3.1) was dispersed in this solution and these dispersions were 
sonicated using a bath sonicator for 20 minutes. The dispersions were then further mixed using a 
T 25 digital ULTRA-TURRAX homogenizer (IKA Works, Inc., Wilmington, NC) at 10,000 rpm 
for 1 min. The organic phase was then slowly added to 10 ml of PVA solution (1% (w/v), 
average Mw 30–70 KDa) and homogenized at 10,000 rpm for 2.5 min. The emulsion was then 
transferred to 125 ml of an aqueous PVA solution (0.1% (w/v), Mw 30-70 KDa) and stirred at 
600 rpm. A vacuum was applied to the aqueous phase for 2.5 hours to evaporate the methylene 
chloride and harden the microspheres. The hardened microspheres were transferred to 50 mL 
centrifuge tubes and collected via centrifugation at 1500 rpm for 2 minutes. The microspheres 
were then washed three times with deionized water (10 mL each time), collected using the same 
centrifugation procedure as before and dried using a freeze dryer. The prepared microspheres 
were stored at 4°C until further use. 
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3.2.2.2 Central composite design 
A 3-factor 5-level central composite design was applied in order to optimize drug loading, burst 
release and lag phase by adjusting the total amount of PLGA, the percentage of DLG7E in the 
polymer blend and the amount of dexamethasone. The design involves preparation of 20 
formulations including 6 center points (CCD-7, 9, 11, 12, 16, 20), 8 edge points (CCD-2, 4, 5, 
10, 13, 14, 18, 19) and 6 star points (CCD-1, 3, 6, 8, 15, 17) as shown in Table 3. 1. 
Table 3. 1. Variables and responses from the central composite design 
  Variables Responses  
Run # Type of 
Design 
Point 
Total Amount 
of PLGA  
(mg) 
DLG7E 
Ratio 
(%) 
Dexamethasone 
 (mg) 
Drug 
Loading  
(%) 
Burst 
Release  
(%) 
Encapsulation 
Efficiency 
(%) 
CCD-1 Star 500.00 20.00 75.00 9.71 37.21 74.44 
CCD-2 Edge 559.46 83.78 60.13 9.29 10.26 95.73 
CCD-3 Star 500.00 60.00 100.00 13.36 13.71 80.16 
CCD-4 Edge 559.46 83.78 89.87 13.18 10.33 95.23 
CCD-5 Edge 559.46 36.22 89.87 11.19 30.13 80.85 
CCD-6 Star 500.00 60.00 50.00 8.66 12.10 95.26 
CCD-7 Center 500.00 60.00 75.00 12.12 18.92 92.92 
CCD-8 Star 400.00 60.00 75.00 12.13 21.08 76.82 
CCD-9 Center 500.00 60.00 75.00 11.47 17.93 87.94 
CCD-10 Edge 440.54 83.78 60.13 11.25 9.75 93.67 
CCD-11 Center 500.00 60.00 75.00 11.55 17.87 88.55 
CCD-12 Center 500.00 60.00 75.00 11.21 15.17 85.94 
CCD-13 Edge 440.54 36.22 89.87 14.32 35.20 84.52 
CCD-14 Edge 559.46 36.22 60.13 8.77 15.20 90.37 
CCD-15 Star 500.00 100.00 75.00 12.84 5.18 98.44 
CCD-16 Center 500.00 60.00 75.00 11.32 14.28 86.79 
CCD-17 Star 600.00 60.00 75.00 9.81 14.27 88.29 
CCD-18 Edge 440.54 83.78 89.87 15.90 12.10 93.84 
CCD-19 Edge 440.54 36.22 60.13 11.23 20.47 93.51 
CCD-20 Center 500.00 60.00 75.00 12.41 15.38 95.14 
 
3.2.2.3 Drug loading 
Drug loading was determined by dissolving approximately 5 mg of dexamethasone-loaded 
PLGA microspheres in 10 ml THF. This solution was filtered (Millex® HV, PVDF 0.45 μm 
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syringe filter) and the dexamethasone concentration was determined using a Perkin Elmer series 
200 HPLC system (Shelton, CT) equipped with a UV absorbance detector (240 nm wave length). 
The mobile phase consisted of acetonitrile/water/phosphoric acid (35/70/0.5, v/v/v). A Zobax 
C18 (4.6 mm × 15 cm, Agilent, Santa Clara, CA) analytical column was used with a flow rate of 
1 ml/min. The injection volume used for drug loading determination was 5 μl. The 
chromatographs were analyzed by PeakSimple™ Chromatography System (SRI instruments, 
Torrance, CA).  
Drug loading was determined as: % drug loading = (weight of drug loaded/weight of 
microspheres) × 100%.  
3.2.2.4 Burst release 
Burst release was determined by incubating approximately 5 mg of microspheres in 100 mL of 
phosphate buffered saline (PBS, 10 mM, pH 7.4) solution at 37 °C. After 24 hours incubation, 10 
mL of PBS was filtrated through a 0.45 μm syringe filter and the dexamethasone concentration 
was determined using the HPLC method described above except that a 20 μl sample was 
injected. 
Burst release was determined as: % burst release = (weight of drug released after 24 
hours/weight of drug loaded in the microspheres) × 100%.  
3.2.2.5 In vitro release testing  
In vitro release testing was performed for the PLGA microsphere/PVA hydrogel (99% 
hydrolyzed, Mw 133 KD) composite formulations. The composites were prepared using a freeze-
thaw method described previously [16]. Briefly, an appropriate amount of PLGA microspheres 
was dispersed into the PVA hydrogel (5% w/v) solution, then this suspension was filled into a 
plastic tubing mold (5 mm inner diameter and 2 cm in length) and subjected to three freeze-thaw 
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cycles consisting of 2 h freezing at −20°C followed by 1 h thawing at room temperature. The 
composites were air dried.  Approximately 2 mg of each formulation was immersed in a 2 ml 
Eppendorf vial containing 1.8 ml of 10 mM PBS (pH 7.4) with 0.1% NaN3 and incubated at 
37 °C under constant agitation. At pre-determined time points, all the release media was removed 
and replenished with fresh media. Sink conditions were maintained throughout. The samples 
were filtered through 0.45 μm syringe filters and the concentration of dexamethasone in each 
sample was determined using the HPLC method as described above. Normalized daily drug 
release from each central composite design formulation was calculated for up to 21 days in order 
to determine the lag phase of the formulations.  
Cumulative dexamethasone release was plotted versus time in the release profile. 
Normalized daily drug release was determined as: amount of drug released between two time 
points/(initial sample weight*duration of two time points). 
3.2.2.6 Particle size evaluation 
An AccuSizer 780A autodiluter particle sizing system (Nicomp, Santa Barbara, CA) was used to 
determine the particle size of the prepared microspheres. Approximately 5 mg of microspheres 
were dispersed in 1 ml of 0.1% (w/v) PVA solution and 100 μl of the dispersion was injected 
into the system for particle size analysis. All measurements were conducted in triplicate and the 
results are reported as the volume based mean particle size ± SD. The standard deviation 
(indicating the distribution of the particle size) was also reported. 
3.2.2.7 Thermal analysis 
A TA Q1000 differential scanning calorimeter (DSC) (TA, New Castle, DE) was used to 
determine the glass transition temperature (Tg) of the prepared microspheres. Modulated DSC 
was performed with the cycle below: the samples were heated at a rate of 3 °C/min from 4°C to 
 41 
 
80 °C at a modulating oscillatory frequency of 1°C/min. The thermograms were analyzed using 
Universal Analysis software (TA Instruments) to determine the glass transition temperatures. 
3.2.2.8 Scanning electron microscopy (SEM) 
A scanning electron microscope (FEI Nova™ NanoSEM 450) equipped with an ETD detector 
was used to evaluate the morphology of the prepared microspheres. Samples were mounted on 
carbon taped aluminum stubs and sputter coated with gold for 1.5 min at 6 mA. Images were 
taken with an accelerating voltage of 2.0 kV and a working distance of 4 mm. 
3.2.2.9 Statistical analysis 
Data collected for drug loading and burst release in each run were analyzed using Design Expert 
software (Version 9, StatEase, Minneapolis, MN, USA) and fitted into linear regression models. 
Analysis of variance (ANOVA) was used to determine the significance of the model and 
parameters. Model correctness was assessed by the lack of fit test. In the case of particle size and 
size distribution, paired Student’s t-test was performed to determine whether there were 
statistically significant differences among the results. 
3.3 Results and discussion 
3.3.1 Central composite design 
The drug loading and burst release for all DoE formulations are shown in Table 3. 1. CCD-18 
has the highest drug loading (15.9%) among all the formulations. The encapsulation efficiency 
(EE, calculated by dividing the actual drug loading by the theoretical drug loading) is 
approximately 93.8%, indicating most of the dexamethasone added was loaded into the 
microspheres. CCD-6 has the lowest drug loading (8.66%) among all the formulations. This is 
due to the low theoretical drug loading of this formulation since the encapsulation efficiency is 
actually similar to that of CCD-18 (EE of CCD-6 is 95.3%). When comparing the encapsulation 
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efficiency of all formulations, CCD-1 has the lowest EE around 75%. This formulation (CCD-1) 
has the highest ratio of low molecular weight PLGA which is likely to cause slower polymer 
precipitation and consequently loss of drug to the aqueous phase. It has been reported that low 
drug encapsulation is associated with slow PLGA precipitation [25]. CCD-15, composed of only 
DLG7E (high molecular weight PLGA) and dexamethasone, was determined to have the lowest 
burst release of 5.18%. Thus, fast microsphere solidification is expected in this case which can 
lead to less surface associated or free dexamethasone present in the formulation [13]. The burst 
release of the CCD-1, 5 and 13 formulations are higher than 30%, which can be explained by 
lower DLG7E ratio and higher initial dexamethasone added into these formulations. A detailed 
statistical description for the DoE results regarding drug loading and burst release are discussed 
below.  
3.3.2 Drug loading 
A significant DoE model was obtained from the study according to the analysis of variance 
(ANOVA) table (Table 3.2) with a p-value less than 0.0001 and Lack of Fit value of 0.2026 
(larger than 0.05). Four terms were included to generate a mathematical model for drug loading 
prediction as shown below (also included in Figure 3.1-C). 
𝑫𝒓𝒖𝒈 𝑳𝒐𝒂𝒅𝒊𝒏𝒈
= 𝟏𝟓. 𝟐𝟗 − 𝟎. 𝟎𝟏𝟕 × 𝑷𝑳𝑮𝑨 − 𝟎. 𝟎𝟓𝟏 × 𝑫𝑳𝑮𝟕𝑬% + 𝟎. 𝟎𝟒𝟒
× 𝑫𝒆𝒙𝒂𝒎𝒆𝒕𝒉𝒂𝒔𝒐𝒏𝒆 + 𝟏. 𝟎𝟕𝟏 × 𝟏𝟎−𝟑 × 𝑫𝑳𝑮𝟕𝑬% × 𝑫𝒆𝒙𝒂𝒎𝒆𝒕𝒉𝒂𝒔𝒐𝒏𝒆 
The p-values for the effect of total PLGA amount, ratio of DLG7E and total dexamethasone 
amount are much smaller than 0.05, indicating that all these factors significantly affect 
microsphere drug loading. The p-value for the interaction term (BC, DLG7E ratio and 
dexamethasone amount) is 0.1133, which is slightly higher than 0.05. A small interaction may 
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exist between these two variables as increasing the amount of dexamethasone will leave 
excessive free drug to interact with the polymers, therefore affecting the drug loading of the 
formulation. The contour plots shown in Figures 3.1-A and 1-B indicate the effects of individual 
factors on the drug loading. Increase in the initial dexamethasone concentration or decrease in 
the total amount of PLGA increased the theoretical drug loading by adjusting the polymer/drug 
ratio and this is reflected in the actual drug loading. A higher ratio of the high molecular weight 
polymer (DLG7E) also leads to higher drug loading. This can be explained by fast precipitation 
of the high molecular weight polymer. When a higher ratio of DLG7E is used, fast solidification 
of the microspheres is expected which will lead to more dexamethasone encapsulation. The 
predicted versus actual drug loading values for all the CCD formulations are shown in Figure 
3.1-D. A linear fit was obtained indicating that the model is valid. 
Table 3.2 ANOVA table of the DoE model used to predict dexamethasone loading.  
 Sum of   Mean F p-value  
Source Squares  df Square Value Prob > F  
Model 57.58  4 14.40 35.49 < 0.0001 Significant 
A-PLGA 14.71  1 14.71 36.26 < 0.0001  
B-DLG7E% 6.43  1 6.43 15.86 0.0012  
C-Dexamethasone 35.29  1 35.29 87.01 < 0.0001  
BC 1.15  1 1.15 2.83 0.1133  
Residual 6.08  15 0.41    
Lack of Fit 4.95  10 0.49 2.17 0.2026 Not Significant 
Pure Error 1.14  5 0.23    
Correlation Total 63.67  19     
 
3.3.3 Burst release 
A significant DoE model (indicated by a p-value less than 0.0001 and Lack of Fit value higher 
than 0.05) for burst release was obtained. The mathematical model for burst release prediction is 
shown below (also included in Figure 3.2-C): 
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𝑩𝒖𝒓𝒔𝒕 𝒓𝒆𝒍𝒆𝒂𝒔𝒆 
= −𝟎. 𝟑𝟕 − 𝟎. 𝟎𝟕𝟕 × 𝑷𝑳𝑮𝑨 − 𝟎. 𝟑𝟗 × 𝑫𝑳𝑮𝟕𝑬% + 𝟏. 𝟓𝟖 × 𝑫𝒆𝒙𝒂𝒎𝒆𝒕𝒉𝒂𝒔𝒐𝒏𝒆
+ 𝟖. 𝟎𝟑 × 𝟏𝟎−𝟒 × 𝑷𝑳𝑮𝑨 × 𝑫𝑳𝑮𝟕𝑬% − 𝟗. 𝟔𝟑 × 𝟏𝟎−𝟑 × 𝑫𝑳𝑮𝟕𝑬%
× 𝑫𝒆𝒙𝒂𝒎𝒆𝒕𝒉𝒂𝒔𝒐𝒏𝒆 + 𝟑. 𝟎𝟐 × 𝟏𝟎−𝟑 × (𝑫𝑳𝑮𝟕𝑬%)𝟐 − 𝟓. 𝟓𝟑 × 𝟏𝟎−𝟑
× (𝑫𝒆𝒙𝒂𝒎𝒆𝒕𝒉𝒂𝒔𝒐𝒏𝒆)𝟐 
More terms were included in this mathematical model indicating a more complex interaction for 
burst release compared to drug loading. The initial burst release is a result of free dexamethasone 
or microsphere surface associated dexamethasone which can be related to the microsphere 
composition as well as the process parameters. In order to rule out the effect of process 
parameters on burst release, all processes were carried out following exactly the same procedures 
including the solvent evaporation time, volume and time for microsphere washing. The process 
is highly reproducible as indicated by the reproducible center points (CCD-7, 9, 11, 12, 16 and 
20) of the DoE.  Since dexamethasone is only slightly soluble in methylene chloride, the 
majority of the drug exists as crystalline particles in the formulation. With change in the DLG7E 
ratio in the polymer composition, the burst release varies significantly as shown in the contour 
plot (Figure 3.2-A). When 80% of DLG7E was added into the polymer blends, the burst release 
remains around 11% although it varies between 9 and 12% according to the total amount of 
polymer and dexamethasone (Figure 3.2-B). The composition of the polymer blends is the most 
important factor affecting the burst release which is also indicated in the ANOVA table (Table 
3.3) where the DLG7E ratio term has the lowest p-value. A significant interaction between the 
DLG7E ratio and the dexamethasone amount was observed (p-value equal to 0.0032). This may 
be explained by dexamethasone having different interactions with different polymers. The square 
of the DLG7E ratio (B^2 in Table 3.3) is also significant. This is because the ratio of the two 
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polymers affects many formulations aspects that may be related to burst release (such as polymer 
precipitation rate during microsphere formation as well as the diffusion rate of drug from the 
surface of the microspheres).   
Table 3.3. ANOVA table of the DoE model to predict dexamethasone burst release. 
 Sum of  Mean F p-value  
Source Squares df Square Value Prob > F  
Model 1226.44 7 175.21 25.46 < 0.0001 Significant 
A-PLGA 38.91 1 38.91 5.65 0.0349  
B-DLG7E% 925.54 1 925.54 134.47 < 0.0001  
C-Dexamethasone 88.61 1 88.61 12.87 0.0037  
AB 10.31 1 10.31 1.50 0.2446  
BC 92.75 1 92.75 13.48 0.0032  
B^2 42.53 1 42.53 6.18 0.0286  
C^2 21.72 1 21.72 3.16 0.1010  
Residual 82.60 12 6.88    
Lack of Fit 64.92 7 9.27 2.62 0.1529 Not Significant 
Pure Error 17.68 5 3.54    
Correlation Total 1309.04 19     
 
3.3.4 Formulation optimization and model validation 
Following the establishment of the models for drug loading and burst release prediction, the 
design space for microsphere composition was optimized to maximize drug loading and 
minimize burst release (in a range of 8 to 12%) based on a batch size of 500 mg PLGA total. 
Figure 3.3 shows the optimized design space using a contour plot of desirability. Desired 
formulations require both a large amount of dexamethasone and a high percentage of DLG7E in 
the total polymer.  
Three points (marked as red crosses in Figure 3.3) in the design space were selected to verify the 
model. Three formulations (V-1, V-2 and V-3) were prepared according to the compositions 
listed in Table 3.4. Burst release and drug loading were analyzed for each formulation and 
compared to the predicted values for model validation. The burst release for all the formulations 
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was close to 10% and the drug loading ranges from approximately 10% to 14%. The actual drug 
loading and burst release for all the formulations tested are consistent with the predicted values 
as shown in Table 3.4, indicating that the models are very predictive. 
Table 3.4. Verification of CCD models using microspheres prepared under conditions within the 
optimized design space (n=3) 
 Composition Drug Loading (%, w/w) Burst release (%, w/w) 
# 
Total 
PLGA  
(mg) 
DLG7E 
ratio  
(%, w/w) 
Dexameth
asone 
(mg) 
Predicted Actual Predicted Actual 
V-1 500 90 60 10.62 10.2 ± 0.09 9.52 9.4 ± 0.3 
V-2 500 80 90 14.38 14.47 ± 0.18 9.45 9.4 ± 0.19 
V-3 500 85 75 12.58 12.31 ± 0.26 9.93 10.27 ± 0.52 
3.3.5 Duration of lag phase 
Bulk degradation is the typical release mechanism for PLGA based microsphere formulations. 
For dexamethasone release from microspheres, the release profile can usually be divided into 
three phases: a burst release, a lag phase with limited drug release and a linear release phase. Our 
previous data has indicated that dexamethasone release during the lag phase (approximately 10 
days) from a 1-month formulation is sufficient to inhibit the foreign body reaction [10, 11, 13]. 
However, it is possible that this may not be the case for microsphere formulations with an 
elongated lag phase that are prepared with high molecular weight PLGA. For example, for a 
microsphere formulation prepared using 75 KDa PLGA, the lag phase was approximately 1 
month [10]. For higher Mw PLGA (such as 113 KDa used in the current study), the lag phase is 
expected to be even longer. Blending low and high molecular weight PLGA has been previously 
used in order to shorten the lag phase [16]. The lag phase was reduced from 1 month to 
approximately 15 days by blending 25 KDa PLGA with 75 KDa PLGA. 
PLGA microsphere/PVA hydrogel composites were prepared for all the microsphere 
formulations in the DoE study considering that the composite coatings are intended for 
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application to biosensors for inhibition of the foreign body reaction. Figure 3.4-A shows the 
release profiles for the initial 21 days for the composite coatings. Release profiles plotted 
according to the different categories of design points (center, edge and star) is also available in 
supplementary data Figure 3.5. The lag phase for CCD-15 started from day 2 and lasted for the 
entire 21 days following a small burst release of less than 10 µg/mg. The low burst release for 
the CCD-15 composite coating is consistent with the low burst observed for the CCD-15 
microspheres. CCD-2 and 6 showed slightly higher burst release (approximately 23 µg/mg) and 
reached a plateau at approximately day 2. The release profiles for the center points (CCD-7, 9, 
11, 12, 16 and 20) are clustered in the middle of the graph with approximately 30 µg/mg burst at 
day 1 and the burst phase continues for these formulations till day 5 when the lag phase begins. 
The extended burst phase is probably due to a delayed effect from the PVA hydrogel. This is 
consistent with our previous observation that the release of dexamethasone from free drug 
embedded PVA hydrogels can last for up to 10 days [26]. CCD-3, 5, 8, and 13 (with high 
dexamethasone loading in the microspheres) have high burst release phases (more than 50 
µg/mL) that also continue for approximately 5 days. The higher burst release exhibited by CCD-
3, 5, 8, and 13 is considered to be due to the large amount of free/surface associated drug in the 
microspheres.  
The burst and lag phases of all formulations were analyzed separately using various kinetics 
models. The models used for analyzing the burst release phase (till day 7) include: the first order 
release model; the Kosmeyer-Peppas model; and the Peppas-Sahlin model. The release kinetic 
parameters are shown in Table 3.5. The first order release model did not provide a good 
approximations since the R square values were small for most of the formulations. The n-value 
obtained using the Kosmeyer-Peppas model is an indication of whether drug release is 
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contributed by Fickian diffusion or polymer swelling (so called Case-II relaxation) [27]. 
However, the n-values obtained for these formulations were beyond the normal range of 0.43 to 
0.85, indicating that a more complex mechanism is involved in the composite system. The 
microspheres are embedded in the PVA hydrogel which acts as an additional barrier for drug 
diffusion. Therefore, drug release was further analyzed using a more complex model, the Peppas-
Sahlin model [28], which returned better R square values (higher than 0.95 for most 
formulations). The Peppas-Sahlin model is able to simulate both the Fickian diffusion of 
dexamethasone from the microsphere surface and Case-II relaxation from the PVA hydrogel. 
With respect to the lag phase (from day 7 to 21), zero order release kinetics did fit the data of all 
formulations (linear release trends were observed with R square values higher than 0.95). Zero 
order drug release indicates concentration independent drug release. This can be explained since 
the release rate limiting factor during the lag phase is mainly the polymer matrix structure 
instead of the drug concentration. 
The lag phases for most of the formulations shown in Figure 3.4-A started at approximately 5 
days. During the lag phase small amounts of drug are released and it is difficult to differentiate 
the various formulations based on their release profiles. Thus, in order to further analyze the lag 
phase, the amount of drug released per day was plotted as a heat map (Figure 3.4-B). The heat 
map allowed better differentiation of the formulations. Analyzing the heat map, it became 
apparent that CCD-15 has the lowest amount of drug released during the 21 day study. This can 
be explained since CCD-15 is composed of only the high molecular weight PLGA. CCD-2 and 
CCD-14 also have relatively lower amounts of drug released during the lag phase compared to 
the other formulations. However, these two formulations have the lowest initial dexamethasone 
loading which will contribute to lower release during the lag phase. It is also apparent from the 
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heat map that the daily drug release for CCD-18 is higher than that of the other formulations at 
most of the time points. The lowest daily dexamethasone release of CCD-18 is from day 7 to day 
9 at approximately 0.15 µg/day, which is slightly less than the reported minimum effective daily 
dose (0.17 µg/day) to control the foreign body response in a rat model [19]. However, a lag 
phase of 2 days can be tolerated (at least in this animal model) without onset of the inflammatory 
response [10, 11, 13]. Considering the high drug loading (15.9%, w/w) along with the burst 
release (12.1%, w/w) and short lag phase of CCD-18, this formulation is optimal among those 
investigated. The short lag phase observed for CCD-18 is probably due to: 1) the extended burst 
phase of this formulation; as well as 2) the reduced lag phase from blending low and high 
molecular weight polymers. The lag phase for the low molecular weight polymer (RG503H) is 
approximately 10 days. With the accumulation of lactic/glycolic acid monomers from hydrolysis 
of the low molecular weight PLGA, the degradation of the high molecular weight PLGA is 
accelerated due to decreased local pH. Accordingly, a continuous release pattern is expected for 
this formulation after the onset of drug release [29]. 
3.3.6 Particle size and size distribution 
Microsphere particle size has been shown to be affected by the formulation composition [30]. 
The star points (6 formulations) from the CCD design were divided into three groups. Each 
group has two formulations that were prepared under the same conditions except that one of the 
independent variables is changed. The three groups are: 1) CCD-1 and 15 where the PLGA 
molecular weight ratio is varied; 2) CCD-8 and 17 where the total amount of PLGA is varied; 
and 3) CCD-3 and 6 where the amount of dexamethasone is varied. Therefore, by analyzing the 
star points in each group, the effect of each independent variable on the formulation 
characteristics was evaluated. The effect of each independent variable on the particle size and 
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size distribution is shown in Figure 3.6. CCD-15 has significantly larger particle size compared 
to CCD-1. Larger particle size is also observed for CCD-17 compared to CCD-8. These 
observations indicate that increasing the amount of high molecular weight polymer as well as the 
initial polymer concentration can lead to larger particle size. This particle size increase can 
possibly be explained by increase in the polymer solution viscosity that occurs under these 
conditions. With high polymer solution viscosity, the energy input required to generate the 
primary emulsion is greater. Therefore larger particle size emulsion droplets were generated for 
formulations with high viscosity compared to those with low viscosity at the same 
homogenization speed (same energy input). It has also been reported that higher particle size is 
associated with higher drug encapsulation which is consistent with observations on these 
formulations [31]. Particle size is also a major factor determining the diffusion rates of 
dexamethasone as the length of the diffusion pathways varies for different sized particles. 
However, no clear trend was observed when comparing the release rates of these formulations. 
This may be explained as the drug release is mainly controlled by the composition of these 
formulations. On comparing CCD-3 and CCD-6, no significant difference in particle size was 
observed since changing the amount of dexamethasone does not affect the viscosity. The 
standard deviation in the particle size for all formulations was approximately 15 µm indicating 
wide distributions with no significant difference between any of the groups. Wide particle size 
distribution is quite common for microspheres prepared via homogenization [32].  
3.3.7 Modulated differential scanning calorimetry (mDSC) 
Star points of the design were analyzed using mDSC to evaluate the thermal properties of the 
formulations as shown in Figure 3.7. Glass transition temperatures for all formulations except for 
CCD-15 were between 45-50 °C. CCD-15 has the highest glass transition temperature (Tg) of 
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approximately 52 °C. The Tg of CCD-15 (composed solely of DLG7E polymer) is similar to the 
Tg of the polymer (52.97 °C, data not shown) indicating that there was no plasticization in the 
microspheres. Only one Tg was detected for all the formulations, suggesting that the polymers 
are miscible in nature and no phase separation occurs. When decreasing the ratio of DLG7E, the 
Tg decreases. Overall, the Tg(s) of these formulations are higher than body temperature. Based 
on this, these formulations are expected to be relatively stable compared to formulations with Tg 
values close to the body temperature following subcutaneous implantation as composite coatings 
for the biosensors. Those formulations with Tg values lower than body temperature may 
experience dose dumping once implanted. 
3.3.8 Microsphere morphology  
In order to investigate the morphology of the prepared microspheres, the star points were also 
evaluated using scanning electron microscopy. As shown from Figure 3.8, most of the 
formulations investigated are spherical. However, some irregular shaped or broken microspheres 
were observed for formulations other than CCD-15. CCD-15 is the only formulation composed 
of a single polymer. Some polymer segregation may occur within the polymer blend 
microspheres and this could cause breakage during the microsphere solidification step. In 
addition, heterogeneous solvent evaporation may occur when polymer blends were used which 
also can explain the morphology observed including the large pores and crevasses. Incomplete 
dexamethasone encapsulation was also observed for CCD-1 which may be a result of slow 
microsphere hardening due to the high ratio of small molecular weight polymer. Incomplete drug 
encapsulation can be correlated with the low encapsulation efficiency (EE=74.44%) for this 
formulation. On the other hand, high encapsulation efficiency (EE=98.44%) was observed for 
the CCD-15 microspheres which were spherical in shape with smooth surfaces. Some non-
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spherical particles were observed for CCD-3 (Figure 3.8-C) and CCD-8 (Figure 3.8-E), which 
appear to be free dexamethasone. This is in agreement with high burst release observed for these 
formulations. In addition, these formulations have a high drug/polymer ratio. On the other hand 
CCD-6 (Figure 3.8-D) and CCD-17 (Figure 3.8-F) which have low drug/polymer ratios, showed 
low burst release. The particle size for these formulations ranges from approximately 10 µm to 
50 µm. A broad size distribution is observed for all the formulations. This is consistent with the 
particle size data shown in Figure 3.6. 
3.4 Conclusions 
The strategy of blending different MW polymers was shown to be effective in reducing the 
microsphere burst release to less than 10% and shortening the release lag phase to less than one 
week. The optimized formulation could potentially be used to prevent the foreign body reaction 
associated with long-term fully implantable glucose sensors. The current study also demonstrated 
that the design of experiments (DoE) principles are beneficial for optimizing PLGA microsphere 
products to achieve the desired release properties. A design space with appropriate formulation 
outcomes (e.g. high drug loading and low burst release) was obtained based on the highly 
predictive DoE models. The optimized design space was shown to be valuable in predicting and 
controlling both drug loading and encapsulation efficiency. According to the design space, 
approximately 85 mg of dexamethasone and 85% of high molecular weight PLGA were required 
in order to achieve a formulation with 15% dexamethasone loading and 10% burst release. The 
design space can also serve as a blueprint to design PLGA blend based microsphere formulations 
with defined release attributes, such as drug loading and burst release. In addition, controlling 
drug release using polymer blending broadens the application of PLGA polymers in long-term 
drug delivery systems. A fundamental understanding of the effect of microsphere composition on 
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the formulation performance was obtained by examining the formulation particle size, thermal 
properties as well as morphologies. Importantly, a novel heat map describing the daily drug 
release was developed to differentiate the various formulations during the lag phase where there 
is low/no drug release. Drug release properties are usually described using release profiles which 
may not be sufficiently detailed to describe the lag phase. In contrast, the drug release lag phase 
was illustrated clearly via the heat map and comparison between various formulations was easily 
made. Such heat maps are especially helpful for researchers who need to screen the release 
properties of a large number of formulations.  
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3.5 Tables and Figures 
Table 3.1. Variables and responses from the central composite design 
  Variables Responses  
Run # Type of 
Design 
Point 
Total Amount 
of PLGA  
(mg) 
DLG7E 
Ratio 
(%) 
Dexamethasone 
 (mg) 
Drug 
Loading  
(%) 
Burst 
Release  
(%) 
Encapsulation 
Efficiency 
(%) 
CCD-1 Star 500.00 20.00 75.00 9.71 37.21 74.44 
CCD-2 Edge 559.46 83.78 60.13 9.29 10.26 95.73 
CCD-3 Star 500.00 60.00 100.00 13.36 13.71 80.16 
CCD-4 Edge 559.46 83.78 89.87 13.18 10.33 95.23 
CCD-5 Edge 559.46 36.22 89.87 11.19 30.13 80.85 
CCD-6 Star 500.00 60.00 50.00 8.66 12.10 95.26 
CCD-7 Center 500.00 60.00 75.00 12.12 18.92 92.92 
CCD-8 Star 400.00 60.00 75.00 12.13 21.08 76.82 
CCD-9 Center 500.00 60.00 75.00 11.47 17.93 87.94 
CCD-10 Edge 440.54 83.78 60.13 11.25 9.75 93.67 
CCD-11 Center 500.00 60.00 75.00 11.55 17.87 88.55 
CCD-12 Center 500.00 60.00 75.00 11.21 15.17 85.94 
CCD-13 Edge 440.54 36.22 89.87 14.32 35.20 84.52 
CCD-14 Edge 559.46 36.22 60.13 8.77 15.20 90.37 
CCD-15 Star 500.00 100.00 75.00 12.84 5.18 98.44 
CCD-16 Center 500.00 60.00 75.00 11.32 14.28 86.79 
CCD-17 Star 600.00 60.00 75.00 9.81 14.27 88.29 
CCD-18 Edge 440.54 83.78 89.87 15.90 12.10 93.84 
CCD-19 Edge 440.54 36.22 60.13 11.23 20.47 93.51 
CCD-20 Center 500.00 60.00 75.00 12.41 15.38 95.14 
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Table. 3.2 ANOVA table of the DoE model used to predict dexamethasone loading 
 Sum of   Mean F p-value  
Source Squares  df Square Value Prob > F  
Model 57.58  4 14.40 35.49 < 0.0001 Significant 
A-PLGA 14.71  1 14.71 36.26 < 0.0001  
B-DLG7E% 6.43  1 6.43 15.86 0.0012  
C-Dexamethasone 35.29  1 35.29 87.01 < 0.0001  
BC 1.15  1 1.15 2.83 0.1133  
Residual 6.08  15 0.41    
Lack of Fit 4.95  10 0.49 2.17 0.2026 Not Significant 
Pure Error 1.14  5 0.23    
Correlation Total 63.67  19     
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Table 3.3. ANOVA table of the DoE model to predict dexamethasone burst release 
 Sum of  Mean F p-value  
Source Squares df Square Value Prob > F  
Model 1226.44 7 175.21 25.46 < 0.0001 Significant 
A-PLGA 38.91 1 38.91 5.65 0.0349  
B-DLG7E% 925.54 1 925.54 134.47 < 0.0001  
C-Dexamethasone 88.61 1 88.61 12.87 0.0037  
AB 10.31 1 10.31 1.50 0.2446  
BC 92.75 1 92.75 13.48 0.0032  
B^2 42.53 1 42.53 6.18 0.0286  
C^2 21.72 1 21.72 3.16 0.1010  
Residual 82.60 12 6.88    
Lack of Fit 64.92 7 9.27 2.62 0.1529 Not Significant 
Pure Error 17.68 5 3.54    
Correlation Total 1309.04 19     
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Table 3.4. Verification of CCD models using microspheres prepared under conditions within the 
optimized design space (n=3) 
 Composition Drug Loading (%, w/w) Burst release (%, w/w) 
# 
Total 
PLGA  
(mg) 
DLG7E 
ratio  
(%, w/w) 
Dexameth
asone 
(mg) 
Predicted Actual Predicted Actual 
V-1 500 90 60 10.62 10.2 ± 0.09 9.52 9.4 ± 0.3 
V-2 500 80 90 14.38 14.47 ± 0.18 9.45 9.4 ± 0.19 
V-3 500 85 75 12.58 12.31 ± 0.26 9.93 10.27 ± 0.52 
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Table 3.5. Release kinetics parameters for dexamethasone release data of DoE formulations 
Burst release 
CCD
-1 
CCD
-2 
CCD
-3 
CCD
-4 
CCD
-5 
CCD
-6 
CCD
-7 
CCD
-8 
CCD
-9 
CCD
-10 
CCD
-11 
CCD
-12 
CCD
-13 
CCD
-14 
CCD
-15 
CCD
-16 
CCD
-17 
CCD
-18 
CCD
-19 
CCD
-20 
first order 
* 
k (d-1) 2.58 5.96 1.57 1.54 2.74 4.24 2.14 2.92 2.09 2.04 2.42 1.80 1.21 3.33 8.91 1.95 2.89 1.40 3.02 2.18 
 Rsqr 0.91 0.86 0.94 0.94 0.97 0.66 0.89 0.98 0.94 0.95 0.93 0.91 0.91 0.98 0.91 0.87 0.90 0.63 0.95 0.87 
Kosmeyer
-Peppas * 
kKP  
(d-1) 
66.6
1 
76.0
4 
62.8
6 
61.7
9 
69.2
0 
68.8
4 
64.1
0 
69.5
3 
65.5
8 
65.1
1 
65.9
3 
62.7
3 
60.1
2 
71.5
1 
83.5
1 
62.8
0 
67.0
4 
60.7
3 
69.1
8 
64.0
8 
n 0.23 0.15 0.27 0.27 0.23 0.17 0.23 0.22 0.24 0.25 0.23 0.24 0.29 0.22 0.10 0.23 0.21 0.22 0.22 0.23 
Rsqr 0.88 0.82 0.90 0.91 0.85 0.86 0.85 0.82 0.87 0.88 0.84 0.86 0.95 0.83 0.74 0.85 0.83 0.93 0.85 0.85 
 
k1 
(d-1) 
101.
1 
124.
1 
91.4 89.3 
106.
1 
110.
4 
98.6 
108.
5 
98.8 97.0 
101.
9 
94.9 83.1 
112.
0 
142.
8 
95.9 
105.
6 
89.3 
107.
3 
98.9 
Peppas-
Sahlin * 
-k2 
(d-1) 
26.0
1 
39.7
2 
20.8
6 
20.2
7 
26.8
6 
33.4
6 
25.2
9 
28.2
1 
24.2
2 
23.4
1 
26.2
3 
23.3
3 
17.6
1 
29.8
1 
51.8
8 
24.2
7 
28.5
6 
22.6
7 
28.2
5 
25.6
1 
m 0.45 0.33 0.51 0.50 0.49 0.37 0.48 0.48 0.49 0.49 0.48 0.49 0.49 0.47 0.26 0.48 0.46 0.41 0.46 0.47 
Rsqr 0.98 0.94 0.99 0.98 0.98 0.98 0.98 0.97 0.99 0.98 0.98 0.98 0.99 0.98 0.88 0.97 0.97 0.99 0.98 0.98 
Lag phase                     
zero order 
k0 
(d-1) 
0.32 0.44 0.25 0.22 0.12 0.86 0.67 0.23 0.32 0.21 0.53 0.64 0.17 0.12 0.28 0.72 0.64 0.87 0.27 0.71 
 F0 
92.9
0 
90.7
4 
94.6
1 
95.1
8 
97.4
9 
81.0
2 
85.0
9 
94.9
7 
92.8
6 
95.4
2 
88.4
0 
86.0
2 
96.3
4 
97.3
9 
94.1
4 
83.9
4 
85.8
7 
80.9
6 
94.0
6 
84.0
8 
 Rsqr 0.98 1.00 0.95 0.99 0.99 0.96 0.95 0.96 0.95 1.00 0.95 0.95 0.98 1.00 1.00 0.94 0.95 0.98 0.97 0.94 
* The equations used for these models are: F=100*[1-Exp(-k1*t)] (First order), F=k1*t^m+k2*t^(2*m) (Peppas-Sahlin), F=kKP*t^n (Kosmeyer-
Peppas), and F=F0+k0*t (Zero order) 
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Figure 3.1. DoE model obtained for dexamethasone loading prediction of microspheres prepared 
using polymer blends. Contour plots (A and B) indicating correlation between drug loading and 
two independent variables. A: DLG7E ratio in the polymer blend and total amount of PLGA (the 
total amount of dexamethasone was set at 85 mg). B: Dexamethasone amount added and total 
amount of PLGA (DLG7E ratio was set at 80%). C: Mathematical equation used to predict 
dexamethasone loading. D: predicted versus actual experimental values based on the model, the 
line indicates a linear fit.    
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Figure 3.2. DoE model obtained for prediction of dexamethasone burst release from 
microspheres prepared using polymer blends. Contour plots (A and B) indicating correlation 
between burst release and two independent variables. A: DLG7E ratio in the polymer blend and 
total amount of PLGA (dexamethasone amount was set as 85 mg). B: Dexamethasone amount 
added and total amount of PLGA (DLG7E ratio was set as 80%)). C: Mathematical equation 
used to predict dexamethasone burst release. D: Predicted versus actual experimental values 
based on the model, the line indicates a linear fit.    
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Figure 3.3. Optimized formulation composition to maximize drug loading and minimize burst 
release. The total amount of PLGA is set at 500 mg. Red crosses (V-1, V-2 and V-3) indicate 
conditions used for model validation.  
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Figure 3.4. Release profile (A) and heat map (B) describing the initial drug release from the 
composite coatings prepared using the microspheres from the DoE study. A: Cumulative 
dexamethasone release was plotted versus time. B: The normalized daily dexamethasone release 
from the coatings was plotted in the heat map. 
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Figure 3.5. Dexamethasone release profiles of DoE formulations prepared at different design 
points: center point formulations (A), edge point formulations (B) and star point formulations (C) 
 
 64 
 
 
Figure 3.6. Particle size and size distribution (volume based) for the star points of the CCD 
microspheres (n=3). Center point parameters were used for these formulations except: 1) the 
DLG7E ratio was different for CCD-1 (20%) and CCD-15 (100%); 2) the dexamethasone 
amount was different for CCD-3 (50 mg) and CCD-6 (100 mg); and 3) the total polymer amount 
was different for CCD-8 (400 mg) and CCD-17 (600 mg). The paired student’s t-test was 
performed to determine whether there were any statistically significant differences. P<0.05 was 
considered as a significant difference.  
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Figure 3.7. DSC thermograms of star points of the CCD microspheres. Center point parameters 
were used for these formulations except: 1) the DLG7E ratio was different for CCD-1 (20%) and 
CCD-15 (100%); 2) the dexamethasone amount was different for CCD-3 (50 mg) and CCD-6 
(100 mg); and 3) the total polymer amount was different for CCD-8 (400 mg) and CCD-17 (600 
mg). 
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Figure 3.8. SEM images of star points of the CCD microspheres. Figures 3.7-A (top left panel), 
B (bottom left panel), C (top middle panel), D (bottom middle panel), E (top right panel), and F 
(bottom right panel) are corresponding to formulations CCD-1, 15, 3, 6, 8 and 17, respectively. 
Center point parameters were used for these formulations except: 1) the DLG7E ratio was 
different for CCD-1 (20%) and CCD-15 (100%); 2) the dexamethasone amount was different for 
CCD-3 (50 mg) and CCD-6 (100 mg); and 3) the total polymer amount was different for CCD-8 
(400 mg) and CCD-17 (600 mg). 
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Chapter 4 
6-month foreign body reaction suppression for glucose sensors using a composite coating 
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Abstract 
The application of dexamethasone releasing poly (lactic-co-glycolic acid) (PLGA) microspheres 
embedded in a poly vinyl alcohol (PVA) hydrogel coatings have been successfully used in the 
suppression of the foreign body reaction to implantable glucose sensors. In the current study, 
dexamethasone loaded PLGA microspheres were prepared blending two types of PLGA 
polymers (RG503H and DLG7E with MW of approximately 25 kDa and 113 kDa, respectively) 
to achieve long-term (6 months) inhibition of the foreign body reaction. The microsphere 
composition was optimized according to the in vitro drug release profiles. The optimized 
microsphere formulation had a composition of DLG7E/RG503H/dexamethasone=21/4/5 
(w/w/w) and released dexamethasone continuously for 6 months when embedded in a PVA 
hydrogel. Combining these microspheres with microspheres composed solely of the DLG7E 
polymer in the PVA hydrogel realized a coating with an even longer (greater than 7 months) 
drug release period in vitro. A heat map was constructed to precisely depict the in vitro daily 
dexamethasone dose released from the coatings in order to understand any lag phase that could 
affect the pharmacodynamic response. According to the in vivo study, the minimum effective 
daily dose to counter chronic inflammation was approximately 0.1 µg per mg of implant. The 
drug loaded implant coatings investigated in vivo showed inhibition of the foreign body reaction 
for 6 months. Such composite coatings composed of PLGA microspheres prepared using 
polymer blends could potentially be used to ensure long-term performance of glucose sensors. 
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4.1. Introduction 
Diabetes mellitus is a chronic metabolic disease affecting approximately 10% of the U.S. 
population and is on a rapid growth trajectory [1]. Monitoring blood glucose levels is critical for 
diabetic patients to prevent hyper- and hypo- glycaemia through allowing enhanced accuracy in 
medication dose control, as well as through adjustment of  diet and life style [2]. The 
advancement of biosensor technology provides new opportunities for diabetic patients to 
continuously monitor their blood glucose levels which cannot be achieved via the old-fashioned 
finger pricking method [3]. The foreign body reaction (FBR), is a major road block to the 
development of a long-term functional implantable glucose sensor [4]. The FBR, a series of 
immunological reactions,  is marked by acute inflammation, chronic inflammation and the 
formation of fibrous capsule which results in the isolation of implants [5]. Currently, only semi-
implantable sensors with a life-time of approximately 7 days are available on the market.  
Various coatings have been developed for glucose sensors to overcome the foreign body reaction 
to extend the sensor life-time including  anti-biofouling coatings [6], porous coatings [7] [8], 
anti-inflammatory drug eluting coating [9-13], and angiogenic agent releasing coatings [14-16]. 
Among these coatings, dexamethasone-releasing coatings are the most promising. Although the 
other coatings were able to prevent the FBR for short periods of time, it is difficult to develop an 
effective long-term coating based on these approaches. Dexamethasone is a potent glucocorticoid 
which can suppress immune cell activation and promote up-regulation of anti-inflammatory 
cytokines [17, 18]. Dexamethasone loaded PLGA microsphere/PVA hydrogel composite 
coatings have been developed to prevent the FBR through continuous release of the drug [10, 13, 
19, 20]. The depletion of dexamethasone can induce a delayed inflammatory reaction and 
therefore the efficacy of these coatings greatly depends on continuous drug release [13, 21]. 3-
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month FBR inhibition was achieved by mixing two different populations of PLGA microspheres 
with complimentary drug release profiles [12].  Blending low and high molecular weight PLGA 
was further utilized to achieve a microsphere formulation with long-term drug release, and a 4.5-
month efficacy was accomplished using this strategy [13]. The low Mw PLGA increases water 
absorption into the polymer matrix and generates acidic oligomers/monomers which facilitates 
the autocatalysis of the high Mw polymer resulting in a continuous release profile. Further 
extending drug release from the microspheres with sufficient efficacy requires fine tuning of the 
formulation composition to achieve appropriate dexamethasone release profiles [22].  
In the current study, dexamethasone loaded PLGA microspheres were prepared via blending two 
PLGA polymers, RG503H and DLG7E, and the ratio of the two polymers was optimized to 
achieve a long-term drug release profile of at least 6 months. The optimized microspheres (with a 
composition of DLG7E/RG503H/dexamethasone=21/4/5, w/w/w) were characterized for 
morphology, particle size, and solid state properties. Three microsphere/PVA hydrogel 
composite coatings were prepared using different microsphere combinations for in vitro and in 
vivo testing: 1) only the optimized microspheres; 2) a mixture of the optimized microspheres and 
microspheres prepared solely with the DLG7E polymer to achieve a longer release profile; and 
3) a mixture of the optimized microspheres, the microspheres prepared solely with the DLG7E 
polymer (to achieve a longer release profile) and an amount free dexamethasone powder (to 
enhance the burst release to ensure the acute inflammatory phase was controlled). In addition, 
dexamethasone stability during a long-term drug release study was monitored using HPLC. 
These composite coatings were applied to dummy sensors and implanted into the subcutaneous 
tissue of rats for evaluation of long-term FBR suppression.  
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4.2. Material and Methods 
4.2.1. Materials 
Dexamethasone was purchased from Cayman Chemical (Ann Arbor, MI), poly (vinyl alcohol) 
(PVA, Mw 30–70 KD), sodium chloride (NaCl, ACS grade), sodium azide (NaN3), sodium 
phosphate dibasic dihydrate (Na2HPO4·2H2O), sodium phosphate monobasic (NaH2PO4) and 
dimethyl sulfoxide (DMSO) were purchased from Sigma–Aldrich (St. Louis, MO). PVA (99% 
hydrolyzed, Mw 133 KD) was purchased from Polysciences, Inc. (Warrington, PA). PLGA 
Resomer® RG503H 5050 (RG503H, inherent viscosity 0.32–0.44 dl/g) was a gift from 
Boehringer-Ingelheim. PLGA 9010 DLG7E (DLG7E, inherent viscosity 0.6-0.8 dL/g) was 
purchased from Lakeshore Biomaterials (Birmingham, AL). RG503H has carboxylic acid end 
groups and DLG7E is end-capped with a lauryl ester group. Methylene chloride (DCM), 
acetonitrile (ACN, HPLC grade), and tetrahydrofuran (THF, HPLC grade) were purchased from 
Fisher Scientific (Pittsburgh, PA). NanopureTM quality water (Barnstead, Dubuque, IA) was 
used for all studies. 
4.2.2.  Methods 
4.2.2.1. Preparation and optimization of PLGA microspheres 
Dexamethasone loaded microsphere formulations were prepared using an oil-in-water (o/w) 
emulsion solvent extraction/evaporation technique as previously reported. Briefly, both PLGA 
polymers at the specific ratio under investigation was dissolved in 2 ml of methylene chloride 
and dexamethasone was dispersed into this solution. Following a 20-minute sonication period in 
a bath sonicator, the dispersion was further mixed using a T 25 digital ULTRA-TURRAX 
homogenizer (IKA Works, Inc., Wilmington, NC) at 10,000 rpm for 1 min. In order to form an 
emulsion, the organic phase was homogenized into a 10-ml PVA solution (1% (w/v), average 
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Mw 30–70 KDa) at 10,000 rpm for 2.5 min. The emulsion was then transferred into a 125 ml 
aqueous PVA solution (0.1% (w/v), Mw 30-70 KDa) and stirred at 600 rpm under vacuum. After 
2.5 hours, hardened microspheres were transferred to 50 mL centrifuge tubes and collected via 
centrifugation at 1500 rpm for 2 minutes. The microspheres were then washed three times with 
deionized water (10 mL each time), recollected using the same centrifugation procedure and 
dried via freeze drying. The prepared microspheres were stored at 4°C until further use. Blank 
microspheres were prepared following the same procedure except that no dexamethasone was 
added. In order to achieve a formulation with long-term drug release of 6 months, microsphere 
composition optimization was conducted using a central composite design (3 factors and 5 
levels) composed of 20 formulations as previously reported [22].  
4.2.2.2. Characterization of optimized PLGA microspheres 
4.2.2.2.1. Particle size and morphology 
The particle size and size distribution was determined using (Nicomp, Santa Barbara, CA). 
Approximately 5 mg of microspheres were dispersed in 1 ml of 0.1% (w/v) PVA solution (30-70 
KDa) and 100 μl of the dispersion were injected into the system for particle size analysis. The 
morphology of the microspheres were determined using a scanning electron microscopy (a FEI 
Nova NanoSEM 450 unit). Samples were mounted on carbon taped aluminum stubs and sputter 
coated with gold for 1.5 min at 6 mA before imaging. 
4.2.2.2.2. Thermal analysis 
A TA Q1000 differential scanning calorimeter (DSC) (TA, New Castle, DE) was used to 
determine the glass transition temperature (Tg) of the prepared microspheres. Modulated DSC 
was performed with the cycle below: the samples were heated at a rate of 2 °C/min from 4°C to 
80 °C at a modulating oscillatory frequency of 1°C per 50 seconds. The thermograms were 
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analyzed using Universal Analysis software (TA Instruments) to determine the glass transition 
temperature. 
4.2.2.2.3. Powder X-ray diffraction (PXRD) 
The crystallinity of the optimized microsphere formulation was determined using PXRD. X-ray 
diffraction patterns were obtained using an X-ray diffractometer (Model D5005, Bruker AXS 
Inc., Madison, WI) with Cu-Kα radiation, a voltage of 40 kV, and a current of 40 mA. All the 
scans were performed with a scanning rate of 2°/min with steps of 0.02° from 5° to 40° at 
2θ ranges. The PLGA polymers, a physical mixture of polymer and dexamethasone, and the 
dexamethasone loaded PLGA microspheres were evaluated using the diffractometer. 
4.2.2.3. Preparation of PLGA microsphere/PVA hydrogel composites  
Cylindrical implants were prepared using a two-piece grooved mold based method after three 
freeze-thaw cycles [23]. Three formulations were prepared (Table 4.1) with different 
microsphere and dexamethasone combinations to achieve various release profiles. 
Table 4.1 Coatings prepared with different microsphere and dexamethasone combinations 
 Microsphere 1 * Microsphere 2 ** 
Additional 
Dexamethasone 
Powder 
Formulation-A 150 mg - - 
Formulation-B 120 mg 30 mg - 
Formulation-C 120 mg 30 mg 3 mg 
Formulation-D BLANK formulation 
* Microsphere 1 was prepared with DLG7E/RG503H/dexamethasone = 21/4/5 (w/w/w) 
** Microsphere 2 was prepared with DLG7E/dexamethasone = 20/3 (w/w) 
 
Briefly, the microspheres were suspended using 1 ml of 5% w/w PVA solution (133 KDa) and 
filled in a 1-mL syringe. The PVA solution was pre-filtrated using 0.22-µm sterile filters to 
ensure sterility. The suspension was sonicated in a bath sonicator for 10 seconds followed by one 
freeze–thaw cycle (2 hour at - 20 °C and 1 hour at ambient temperature). The partially thickened 
suspension was fed into a 2-piece mold with 1.5-mm grooves. The dummy sensors (silicon chips 
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with dimension of 5 × 0.5 × 0.5 mm) were sandwiched between the two mold pieces and were 
then subjected to additional two freeze thaw cycles. The coated dummy sensors were air dried 
and cut into 7-mm length implants. The grooves in the mold are 1.5-mm diameter. To ensure size 
consistency of each implant, dummy sensors are placed in the center of the groove between the 
two pieces of the mold. Sterile tools (e.g. vials, tubes, twizzles and containers, etc.) were used in 
the coating process. All the procedures were conducted in a laminar flow hood under sterile 
conditions. Blank formulations were also prepared using blank PLGA microspheres without 
dexamethasone.  
4.2.2.4. Drug loading 
Approximately 5 mg of dexamethasone-loaded PLGA microsphere/PVA hydrogel composites 
were dissolved in 10 ml DMSO to determine the drug loading. These solutions were filtered 
(Millex® HV, PVDF 0.45 μm syringe filter) and subjected to HPLC analysis with 5 μl of 
injection volume. A Perkin Elmer series 200 HPLC system (Shelton, CT) was equipped with a 
UV absorbance detector (240 nm wave length for dexamethasone analysis). 
Acetonitrile/water/phosphoric acid (35/70/0.5, v/v/v) was used as the mobile phase. A Zobax 
C18 (4.6 mm × 15 cm, Agilent, Santa Clara, CA) analytical column was used with a flow rate of 
1 ml/min. The chromatographs were analyzed using a PeakSimple™ Chromatography System 
(SRI instruments, Torrance, CA).  
Drug loading was determined as: % drug loading = (weight of drug loaded/weight of 
microspheres) × 100%. 
4.2.2.5. In vitro drug release  
In vitro release testing was performed on the PLGA microsphere/PVA hydrogel (99% 
hydrolyzed, Mw 133 KD) composites. The composites were prepared using a freeze-thaw 
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method described above except that no dummy sensors were used. Approximately 5 mg 
composite samples were immersed in 5 ml of 10 mM PBS (pH 7.4) with 0.1% NaN3 and 
incubated at room temperature (37 °C) under constant agitation. At pre-determined time points, 
all the release media was removed and replenished with the same volume of fresh media. After 5 
days, the volume of release media was changed to 1 ml and sink conditions were maintained 
throughout. The samples were filtrated through 0.45 μm syringe filters and the concentration of 
dexamethasone in each sample was determined using the HPLC method described above. 
Cumulative percent release and the normalized daily drug release were calculated during the 
release period in order to obtain the release profile and a heat map, respectively.   
Cumulative percent release = (total amount released at sampling time/total amount loaded) × 
100.  
Normalized daily drug release = amount of drug released between two time points/(initial sample 
weight*duration of the two time points). 
4.2.2.6. In vivo pharmacodynamics study of composite coated dummy sensors 
PLGA/PVA composite coated dummy sensors prepared in section 4.2.2.3.1 were implanted into 
the interscapular subcutaneous tissue of male Sprague-Dawley rats (weighing ~ 200 g, n=3) 
using 16-gauge thin wall needles. During the implantation procedure, the rats were under 
anesthesia (2% isoflurane in oxygen). Before implantation, the back of each animal was shaved 
and wiped with betadine solution. All of the procedures were conducted under aseptic 
conditions. Four composites were implanted per rat and the implants were kept for 7 days, 14 
days and 1, 2, 3, 4, 5, 6 months. At the end of the 6 months, rats were sacrificed. The 
subcutaneous tissue surrounding the implants were harvested and fixed in 10% buffered formalin 
solution. Paraffin blocks were prepared for the tissue sections and a blinded histological 
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evaluation was performed following hematoxylin and eosin (H&E) staining. Tissue samples 
were observed and digitally stored using an Olympus microscope (model BX51, Olympus 
America, Melville, NY). All animal studies were reviewed and approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Connecticut prior to any animal 
studies.  
4.3. Results and discussion 
4.3.1. Microsphere optimization 
In order to achieve an optimized microsphere composition, 20 formulations were prepared 
according to a central composite design. The composition of each formulation is listed in Table 
4.1. DoE models were previously obtained for the prediction of drug loading and burst 
release.[24] Figure 4.1 shows the heat map for drug release from the 20 formulations over 
approximately 7 months. Formulation 18, with a composition of 
DLG7E/RG503H/dexamethasone of approximately 21/4/5 (w/w/w), resulted in the overall 
highest drug release on a daily basis compared to the other formulations, making it the optimal 
formulation to carry out 6-month in vivo testing. Formulation 15, with a composition of 
DLG7E/dexamethasone of approximately 20/3 (w/w), resulted in the longest lag phase of more 
than 4 months followed by rapid dexamethasone release starting from approximately 4.5 months. 
By the end of 7 months, the daily drug release from this formulation is still approximately 1 µg 
per mg of implant. Therefore, it was considered that a combination of Formulation-15 and 
Formulation-18 in the composite coating may lead to a formulation with a continuous drug 
release period longer than 7 months. All other formulations presented a very low daily dose (< 
0.05 µg per mg of implant) of dexamethasone starting from approximately 41 days. Several 
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formulations (e.g. formulations-2, 5, 10, 13, and 14) presented a very low daily dexamethasone 
dose after approximately 7 days.  
4.3.2. Particle size and morphology 
The composition of formulation-18 was determined to be suitable to achieve 6-months 
continuous drug release. Accordingly, the morphology and particle size distribution of this 
formulation was obtained (Figure 4.2). As shown from Figure 4.2-A and B, the microspheres are 
spherical with smooth surfaces. Their smooth surfaces indicate that no or little dexamethasone is 
present on the surface of these microspheres and this contributes to the low burst release 
observed for these formulations. The volume based mean particle size of this formulation is 
34.26 ± 13.44 µm with a range of 2 to 75 µm as shown in Figure 2-C. The polydispersity of this 
formulation is typical of microspheres prepared using the emulsion-solvent evaporation method 
[13]. 
4.3.3. Solid state characterization of microspheres 
The optimized microspheres were characterized for their thermal properties using TGA (Figure 
4.3-A), and mDSC (Figure 4.3-B, C). From the TGA thermogram, both the DLG7E and 
RG503H polymers started to lose weight at approximately 270 ˚C and the weight loss continued 
until less than 5% of the weight was left at approximately 350 and 360 ˚C, respectively. Two 
phases were observed for dexamethasone weight loss with a first phase from approximately 270 
˚C to 340 ˚C where approximately 70% of the weight was lost and a second phase from 
approximately 340 ˚C to 450 ˚C where the remaining 25% of the weight was lost. The optimized 
microsphere formulation and the physical mixture presented similar 2-phase patterns except that 
approximately 90% of the weight was lost during the first phase. This pattern is between that of 
the pure dexamethasone and the PLGA polymer. In addition, no significant weight loss was 
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observed for this microsphere formulation within 100 ˚C, indicating that there was no or an 
insignificant amount of residual solvent in the formulation and the microspheres were completely 
dried during the freeze drying process.  
The total heat flow from the DSC thermogram is shown in Figure 4.3-B. Crystalline 
dexamethasone has a melting temperature (Tm) of approximately 262 ˚C which is very difficult 
to observe via DSC as this temperature is very close to its decomposition temperature. Therefore 
mDSC was performed in the temperature range (4-80 ˚C) to detect the thermal transition of 
PLGA. Endothermal peaks at approximately 50 ˚C were observed for the polymers, the physical 
mixture and the microspheres. The endothermic event observed is a result of both the PLGA 
polymer glass transition and the enthalpy of relaxation. Both the physical mixture and the 
microsphere formulation presented broader endothermic peaks (with non-smooth transitions 
circled in Figure 4.3-B-d2 and Figure 4.3-B-e2) compared to individual polymers. This is 
probably due to the presence of two polymer phases.  
The reverse heat flow was analyzed to determine the glass transition temperatures (Tg) of the 
polymers, the physical mixture and the microspheres (Figure 4.3-C). The RG503H polymer 
presented a Tg of approximately 49.2 ˚C and DLG7E had a slightly higher Tg (approximately 
53.1 ˚C) due to its higher molecular weight and hydrophobicity. In spite of the non-smooth 
transition observed for the polymer physical mixture, only one glass transition was observed 
from the reversible heat flow (Figure 4.3-C-d3). In contrast, a non-smooth transition was 
observed during the glass transition region of the microsphere formulation (Figure 4.3-C-e3). 
From the non-smooth transition observed in the reversible heat flow, two Tgs were determined at 
approximately 48.3 ˚C and 52.3 ˚C, indicating that two polymer phases exist in the formulation. 
It is interesting that two Tgs were observed for the microsphere formulation but not in the 
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polymer physical mixture. This is possibly due to the low concentration of one polymer 
(RG503H) and inefficient heat transfer between the two polymer phases in the physical mixture 
which can reduce modulated heat flow signals. Good heat transfer between the different phases 
in the microsphere formulation is expected. Although the Fox equation can be used to determine 
the composition of each polymer phase in the microspheres according to the Tg values [25], it is 
difficult to perform such estimation here as the glass transition temperatures of these two 
polymers are very close. The overall Tg of the microsphere formulation is relatively high when 
compared to the body temperature (37˚C), and this is beneficial for the microspheres to maintain 
stability during the drug release phase in vivo.  
Dexamethasone encapsulated in PLGA microspheres prepared using the solvent evaporation 
method have been shown to be crystalline using polarized light microscopy [26]. However, the 
PXRD pattern has never been obtained for such microspheres. PXRD diffraction profiles of the 
PLGA polymers, dexamethasone, the physical mixture and the microspheres are shown in Figure 
4.4. Both the DLG7E and RG503H polymers showed broad bumps without diffraction peaks 
indicating their amorphous nature. Typical dexamethasone diffraction peaks were observed for 
both the physical mixture (Figure 4.4-D) and the microsphere formulation (Figure 4.4-E) 
indicating that dexamethasone is crystalline in the microspheres. The dexamethasone peak 
observed from the physical mixture is not as sharp as from the microspheres. This is probably 
because the DLG7E polymer is in the form of large particles (1-3 mm) rather than fine powder 
which affects its packing in the sample holder. The microspheres can pack nicely in the holder 
and a sharper diffraction pattern was therefore observed. Considering that PXRD has a fairly 
high (2-3%) detection limit for mixed materials, the clear dexamethasone diffraction peaks 
observed from the microspheres can also be attributed to their high dexamethasone loading 
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(approximately 15%, w/w). The microsphere preparation process preserved the crystalline nature 
of dexamethasone, which is beneficial to achieve long-term stability during drug release both in 
vitro and in vivo. 
4.3.4. In vitro release  
Three composite formulations were prepared using different combination of microsphere and 
dexamethasone to achieve various release profiles. The drug loadings in the composite coatings 
for formulation A, B and C are 6.91%, 6.6% and 9.7%, respectively. The cumulative % release 
of dexamethasone from the three formulations is shown in Figure 4.5-A. All the formulations 
presented very similar release patterns with an initial burst release phase, an approximate10-day 
low dose release phase, and multiple distinct linear drug release phases. Within 24 hours, both 
formulations A and B had approximately 13% burst release while formulation C had a burst 
release of approximately 30% due to free dexamethasone loaded in the composites. The 1st linear 
release phase was observed starting from approximately day 15 and lasted for approximately 1.5 
months. This phase is probably due to the initiation of RG503H polymer degradation. Starting 
from approximately 2 months, the drug release was reduced and a 2nd linear release phase was 
observed lasting for approximately 2 months. After approximately 4.5 months, drug release 
started to increase and a 3rd linear drug release phase was observed from 4.5-months to 
approximately 5.5-months followed by a 4th drug release phase when drug release gradually 
reduced and complete release was reached. By end of the 8-month testing period, all 
formulations reached approximately 85% cumulative release.  
Although the release profiles gave a general idea of drug release patterns from the composites, it 
is difficult to obtain the actual daily dose of dexamethasone released from each formulation and 
therefore distinguish between the different formulations. This information is critical to evaluate 
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the efficacy of the coatings to counter chronic inflammation when implanted. Therefore, a heat 
map was generated to depict the dose of drug released per day for these formulations (Figure 4.5-
B). Dexamethasone was continuously released during the entire incubation period for all 
formulations and seven drug release phases were observed for each formulation. Burst release 
was observed during the first day with approximately 10 µg dexamethasone released per mg of 
implant for formulations A and B. For formulation C, the dose for day 1 release was 
approximately 30 µg/mg (red region of the heat map) due to additional free dexamethasone 
added into the implant. Following the burst release, dexamethasone daily release was maintained 
at approximately 0.4 µg per mg of implant (yellow regions in the heat map) except for two 
periods when the daily dose was approximately 0.1 µg per mg of implant (green regions in the 
heat map). Dexamethasone release duration for formulations B and C are approximately 1 month 
longer than formulation A due to the addition of Microsphere 2, which was prepared using only 
DLG7E polymer. Formulations prepared using only DLG7E polymer had been previously 
reported to present a very long lag phase of approximately 4.5 months, making it unsuitable to 
achieve continuous dexamethasone release [13]. However, by mixing the two microsphere 
formulations discussed in this study a coating was achieved with the longest reported 
dexamethasone release (more than 7 months), which successfully eliminated the long lag phase 
associated with the DLG7E based microspheres.  
4.3.5. Stability of dexamethasone 
In order to achieve optimal conditions for in vitro release testing, dexamethasone stability in 
different phosphate buffers (10 and 100 mM) at pH 7.4 was investigated at 37˚C. According to 
the HPLC method developed, dexamethasone is eluted with a retention time of approximately 
5.2 min. The buffer concentration had a significant effect on dexamethasone degradation (Figure 
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4.7). Approximately 98% of dexamethasone remain stable after 3-days incubation at 37˚C in 10 
mM phosphate buffer and no degradation peaks were observed. In contrast, in 100 mM 
phosphate buffer, approximately 20% of dexamethasone degraded within 3 days and two major 
degradation peaks were observed following the dexamethasone peak (data not shown). 
Therefore, release testing was conducted using 10 mM phosphate buffer and the media was 
replaced twice per week to ensure dexamethasone stability for accurate quantification.  
The HPLC diagrams of dexamethasone released at various time points (up to 7 months) are 
shown in Figure 4.6 No major degradation peaks were observed at any of the time points, 
indicating that dexamethasone is stable inside the microspheres over the 7-months period. It is 
interesting that dexamethasone remains stable when loaded in the microspheres under 
incubation, considering that the microspheres are fully hydrated internally. It is possible that 
dexamethasone presents as both crystalline and solution state inside the microspheres. It is likely 
that the solution state exists within the microspheres only transiently, and therefore the dissolved 
dexamethasone is released from the microspheres before degradation may occur.  
4.3.6. In vivo pharmacodynamics 
The coated dummy sensors were implanted into the subcutaneous tissue of normal rats to 
determine the in vivo efficacy of the coatings (Figure 4.8 and 4.9). Development of acute 
inflammation (day 7), chronic inflammation (day 14), formation and maintenance of a fibrous 
capsule (from 1 to 7 month) was observed for Formulation-D, which had no dexamethasone 
loaded. All three formulations loaded with dexamethasone were able to successfully inhibit the 
foreign body reaction for 6 months. During the burst phase, no inflammatory cell infiltration was 
observed within 7 days for all three formulations (Formulation-A, B, and C). The lowest 24-h 
burst dose was observed for Formulation-B (no additional free dexamethasone loaded) at 
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approximately 8.3 µg per mg of implant. This dose was sufficient to inhibit acute inflammation. 
Following burst phase, no inflammatory cell infiltration or fibrous encapsulation was observed at 
all time points, with the exception of Formulation-C at the 3 month time point where a mild 
inflammatory cell infiltration was observed (neutrophils, macrophages, and lymphocytes). The 
inflammatory cell infiltration at this time point is possibly due to the low dose of dexamethasone 
release from this formulation during the 2-3 month period (less than 0.1 µg per mg of implant per 
day). However, with the continuous dexamethasone release from the implant, the mild 
inflammatory cell infiltration was not able to develop to the formation of foreign body capsule. 
In contrast, the daily dose was above 0.1 µg/mg for the other two formulations (Formulation-A 
and B).  
Dexamethasone has long been used to counter foreign body reactions to implanted devices [27-
29]. Due to the high potency of dexamethasone, very low doses are needed to exert a local effect. 
The US FDA approved a 0.7 mg dexamethasone implant (Ozurdex®) in PLGA for the treatment 
of macular edema following retinal vein occlusion in 2009 and for the treatment of noninfectious 
intermediate and posterior uveitis in 2010 after a series of successful clinical trials [30-33]. The 
weight of each piece of Ozurdex® is approximately 1 mg and the efficacy of Ozurdex® can last 
for 3-6 months with approximately 90% of dexamethasone released within 1 month [34]. 
Therefore, the average daily maintaining dose for the remaining 5 months is approximately 
0.47µg per mg of implant, which is higher than the daily dose (0.1-0.4 µg) from the implants 
investigated in this study, indicating the potential safety of these formulations.  
4.4. Conclusions 
The current study established a 6-month dexamethasone releasing coating to counter FBR to 
implantable sensors. This formulation has the longest duration of action among any reported 
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dexamethasone implant thus far. Long-term continuous drug release was achieved from PLGA 
microspheres prepared with polymer blends, indicating that blending different MW PLGAs is a 
promising strategy to adjust drug release profiles. In order to obtain detailed information 
regarding the entire drug release phase, a heat map was used and shown to be advantageous over 
traditional release profiles to distinguish formulations with optimal daily dose and release 
duration. The heat map was helpful to understand dose-response correlations during each release 
phase for long-term drug release formulations. Importantly, the minimum effective 
dexamethasone daily dose during the acute and chronic inflammatory phases will provide 
guidance for future coating design for long-term biosensors. The successful development of a 
long-term effective composite coating paves the way towards the realization of long-term, totally 
implantable continuous glucose monitoring systems. 
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4.5. Tables and Figures 
Table 4.1 Coatings prepared with different microsphere and dexamethasone combinations 
 Microsphere 1 * Microsphere 2 ** 
Additional 
Dexamethasone 
Powder 
Formulation-A 150 mg - - 
Formulation-B 120 mg 30 mg - 
Formulation-C 120 mg 30 mg 3 mg 
Formulation-D BLANK formulation 
* Microsphere 1 was prepared with DLG7E/RG503H/dexamethasone = 21/4/5 (w/w/w) 
** Microsphere 2 was prepared with DLG7E/dexamethasone = 20/3 (w/w) 
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Figure 4.1. Heat map illustrating dexamethasone release from composites prepared with 
microspheres according to the central composite design. (n=2 for each time point) 
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Figure 4.2. SEM micrographs of the optimized PLGA microspheres (prepared using a 
composition of DLG7E/RG503H/dexamethasone = 21/4/5, w/w/w) at 500X (A) and 1000X (B) 
magnification. Volume based particle size distribution of the microspheres (C) obtained using an 
AccuSizer 780A autodiluter particle sizing system. Approximately 140,000 particles were 
analyzed using the particle sizer. 
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Figure 4.3. TGA thermograms of: RG503H polymer (a1); DLG7E polymer (b1); dexamethasone 
(c1); physical mixture of RG503H:DLG7E:dexamethasone = 4:21:5 (w/w/w) (d1); and 
microsphere 1 (e1). DSC thermogram of: RG503H polymer (a2); DLG7E polymer (b2) 
dexamethasone (c2); physical mixture of RG503H:DLG7E:dexamethasone = 4:21:5 (w/w/w) 
(d2); and microsphere 1 (e2). Reverse heat flow thermograms of: RG503H polymer (a3); 
DLG7E polymer (b3); dexamethasone (c3); physical mixture of 
RG503H:DLG7E:dexamethasone = 4:21:5 (w/w/w) (d3); and microsphere 1 (e3). The 
nonsmooth transitions of heat flow were circled in B and C.  
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Figure 4.4. PXRD diffraction profiles of: RG503H polymer (A); DLG7E polymer (B); 
dexamethasone (C); physical mixture of DLG7E:RG503H:dexamethasone = 21:4:5 (w/w/w) (D); 
and microsphere 1 (E) 
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Figure 4.5. In vitro dexamethasone release profiles (A) and heat map (B) of composite coatings 
prepared using different combinations of microspheres. (n=3 for each time point) 
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Figure 4.6. HPLC diagram of: dexamethasone standard (A); and dexamethasone released from 
composite coatings following incubation for 7-days (B); 1-months (C); 2-months (D); 3-months 
(E); 4-months (F); 5-months (G); 6-months (H); and 7-months (I). 
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Figure 4.7. Dexamethasone degradation kinetics in 10 mM and 100 mM phosphate buffer. 
Approximately 20 mL dexamethasone solution (25 µg/mL) was incubated at 37˚C and 
percentage remaining dexamethasone was quantified using HPLC.  
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Figure 4.8. In vivo pharmacodynamics of implanted composite coated dummy sensors in rats 
following 7-day, 14-day, 1-month and 2-month implantation (top to bottom). From left column 
to right column are normal tissue, formulation-A, B, C and D. Stars indicate where the implants 
were located, the red arrows indicate infiltrated inflammatory cells, the green arrow indicates 
activated fibroblasts present during the transitional phase from acute to chronic inflammation, 
and the yellow arrows indicate a fibrous capsule formed around the implants. 
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Figure 4.9. In vivo pharmacodynamics of implanted composite coated dummy sensors in rats 
following 3-, 4-, 5-, and 6-month implantation (top to bottom). From left column to right column 
are normal tissue, formulation-A, B, C and D.  Stars indicate where the implants were located, 
the red arrows indicate infiltrated inflammatory cells and the yellow arrows indicate a fibrous 
capsule formed around the implants. 
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Chapter 5 
Effect of PLGA microsphere degradation on glucose transport through composite coatings 
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Abstract 
The aim of this study was to understand the polymer degradation and drug release mechanism 
from PLGA microspheres embedded in a PVA hydrogel. Two types of microspheres were 
prepared with different molecular weight PLGA polymers (approximately 25 and 7 kDa) to 
achieve different drug release profiles, with a 9-day lag phase and without a lag phase, 
respectively.  The kinetics of water uptake into the microspheres coincided with the drug release 
profiles for both formulations. For the 25 kDa microspheres, minimal water uptake was observed 
in the early part of the lag phase followed by substantial water uptake at the later stages and in 
the drug release phase. For the 7 kDa microspheres, water uptake occurred simultaneously with 
drug release. Water uptake was approximately 2-3 times that of the initial microsphere weight 
for both formulations. The internal structure of the PLGA microspheres was evaluated using low 
temperature scanning electron microscopy (cryo-SEM). Burst drug release occurred followed by 
pore forming from the exterior to the core of both microspheres.  A well-defined 
hydrogel/microsphere interface was observed. For the 25 kDa microspheres, internal pore 
formation and swelling occurred before the second drug release phase. The surface layer of the 
microspheres remained intact whereas swelling, and degradation of the core continued 
throughout the drug release period. In addition, microsphere swelling reduced glucose transport 
through the coatings in PBS media and this was considered to be a as a consequence of the 
increased thickness of the coatings.  The combination of the swelling and microdialysis results 
provides a fresh understanding on the competing processes affecting molecular transport of 
bioanalytes (i.e. glucose) through these composite coatings during prolonged exposure in PBS.   
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5.1 Introduction 
Poly (lactic-co-glycolic acid) (PLGA) based parenteral formulations are widely used for 
sustained delivery of various therapeutic entities such as small molecules, peptides as well as 
proteins [1-3]. There are currently twelve PLGA/PLA based microsphere products available on 
the market, including Risperdal® Consta®, Sandostatin® LAR, Zoladex®, and Lupron Depot®. 
This type of formulation is suitable for achieving long-term efficacy with reduced dosing 
frequency and is typically administered via the intramascular (I.M.) and subcutaneous (S.C.) 
routes. It is critical to understand the drug release mechanism from microspheres in order to 
design and develop formulations with controlled release kinetics. Diffusion and 
degradation/erosion are two main release mechanisms associated with this type of formulation. 
The initial phase of drug release is usually considered to be controlled by drug diffusion from the 
surface and the later stage of drug release is associated with degradation and erosion[4]. 
Hydration takes place with great speed relative to erosion when the microspheres are immersed 
in an aqueous buffer. Microsphere hydration is followed by polymer chain degradation which 
occurs throughout the polymer matrix in the form of random hydrolysis and leads to the 
formation of internal pores [5].  
However, the detailed underlying mechanisms/processes of drug release from PLGA 
microspheres are not yet fully understood. Complex mechanisms/processes have been proposed 
by researchers regarding degradation and drug release from various types of PLGA microspheres 
[5, 6]. Heterogeneous bulk degradation was proposed as two distinctive glass transition 
temperatures were observed in different PLGA microspheres with varied copolymer 
compositions [7]. Such heterogeneity can be partly attributed to a pH gradient from the interior 
(low pH) to the surface (high pH) of the microspheres, due to accumulation of hydrolyzed 
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lactic/glycolic acid monomers and oligomers within the microspheres [8, 9]. This occurs as a 
result of the slower diffusion of lactic/glycolic acid monomers and oligomers compared to buffer 
components [8]. An often neglected fact is that water diffusion from the outside to the inside 
(swelling) due to the increased osmotic pressure can lead to a higher degree of dilution of the 
acidic components close to the surface. Swelling is an important process during PLGA 
microsphere degradation.  Initial microsphere swelling has been reported to form a skin layer on 
the surface as a result of pore-closing [10] and therefore delay the initial drug release which may 
cause an apparent lag phase. Initial microsphere swelling has also been reported to cause burst 
release [11]. Swelling and water uptake in clonidine-loaded PLGA microspheres during the 
second drug release phase was reported by Gaignaux et al[12]. However, the method used by 
these researchers which involved measuring filtered wet microspheres may have resulted in 
significant error due to adsorbed water on the microsphere surfaces. More recent findings have 
indicated that microsphere swelling with significant volume increase coincides with the onset of 
the second drug burst release phase [13, 14]. Microsphere swelling is possibly a result of 
polymer chain relaxation due to elevated temperature and increased osmotic pressure resulting 
from accumulation of dissolved drug and degradation species [15]. Unfortunately, the water 
uptake into these microspheres was not reported in these studies.  
The microsphere internal structure may significantly affect drug release. In protein loaded 
microspheres prepared using the double emulsion-solvent evaporation method, pore closing and 
opening events were observed to affect drug release [10, 16]. In a multi-layer reservoir type 
microsphere formulation, rupture of the outer layer caused by inner layer swelling was observed 
and shown to govern drug release [17]. Microsphere structure collapse and particle 
agglomeration have been reported during the later stages of drug release [18, 19]. While pore 
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formation is generally believed to happen internally, detailed pore morphology has yet to be 
revealed. Microsphere morphology change during drug release is usually determined via 
scanning electron microscopy (SEM). To evaluate the internal structure of microspheres, 
samples are usually incubated for a period of time, then collected, dried and 
cut/crushed/fractured before SEM imaging [10, 16, 19, 20]. This sample preparation process may 
create defects which may alter the internal structure of the particles. Accordingly, low 
temperature scanning electron microscopy (cryo-SEM) may be a better technique to investigate 
microsphere internal structure since the samples are flash-frozen in liquid nitrogen and then 
freeze-fractured to maintain the structural characteristics for imaging. This technique has been 
successfully used for biological samples [21]. To the best of our knowledge, cryo-SEM has never 
been used to investigate PLGA microsphere internal structure changes. 
Dexamethasone containing PLGA microspheres embedded in poly vinyl alcohol (PVA) 
hydrogels have been developed as composite coatings for subcutaneous implants to inhibit the 
foreign body reaction [22-27]. The efficacy of these coatings was shown to be dependent upon 
the drug release profile from the PLGA microspheres [26, 28]. Dexamethasone release from 
PLGA microspheres can typically be divided into three phases, a burst release phase, a lag phase 
and a second drug release phase following a bulk degradation mechanism. When embedded in 
PVA hydrogels, the burst release phase has been shown to be slightly extended due to the 
diffusional resistance caused by the hydrogel [29]. The lag phase and second drug release phase 
are mainly controlled by drug release from the microspheres [30]. The PVA hydrogels maintain 
a neutral pH and are permeable to water and other small molecules. The PVA hydrogel also 
provides a protective layer to maintain microsphere structure during drug release [20]. Therefore, 
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investigating the composite coating will provide valuable information regarding drug release 
from PLGA microspheres.  
In this study, two different PLGA microsphere formulations with different drug release profiles 
were prepared. PLGA microsphere/PVA hydrogel composite coatings were evaluated from three 
aspects: 1) the swelling properties (water uptake) determined as the swelling ratio, 2) internal 
structure change evaluated using cryo-SEM, and 3) glucose diffusion through the coating 
investigated using microdialysis. The swelling and internal structure change of the coatings may 
facilitate understanding of the physicochemical properties of the composites for glucose sensors 
coating design.  
5.2 Material and Methods 
5.2.1 Materials 
Dexamethasone was purchased from Cayman Chemical (Ann Arbor, MI), poly (vinyl alcohol) 
(PVA, Mw 30–70 KD), sodium chloride (NaCl, ACS grade), sodium azide (NaN3), sodium 
phosphate dibasic dihydrate (Na2HPO4·2H2O), sodium phosphate monobasic (NaH2PO4) and 
dimethyl sulfoxide (DMSO) were purchased from Sigma–Aldrich (St. Louis, MO). PVA (99% 
hydrolyzed, Mw 133 KD) was purchased from Polysciences, Inc. (Warrington, PA). PLGA 
Resomer® RG503H 5050 (RG503H, with molecular weight approximately 25 kDa) was a gift 
from Boehringer-Ingelheim. PLGA 5050 DLG1A (DLG1A, with molecular weight 
approximately 7 kDa) was purchased from Lakeshore Biomaterials (Birmingham, AL). 
Methylene chloride (DCM), acetonitrile (ACN, HPLC grade), and tetrahydrofuran (THF, HPLC 
grade) were purchased from Fisher Scientific (Pittsburgh, PA). NanopureTM quality water 
(Barnstead, Dubuque, IA) was used for all studies. 
5.2.2 Methods 
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5.2.2.1 Preparation of PLGA microspheres 
Dexamethasone loaded microspheres were prepared using an oil-in-water (o/w) emulsion solvent 
extraction/evaporation technique. Two microsphere formulations were prepared using either 
RG503H or DLG1A PLGA. 500 mg of PLGA were dissolved in 2 ml of methylene chloride and 
50 mg of dexamethasone were dispersed in this solution and these dispersions were sonicated 
using a bath sonicator for 20 minutes. The dispersions were then further mixed using a bench top 
homogenizer (T25, IKA Works, Inc., Wilmington, NC) at 10,000 rpm for 1 min. The organic 
phase was then slowly added to 10 ml of PVA solution (1% (w/v), average Mw 30–70 KDa) and 
homogenized at 10,000 rpm for 2.5 min. The emulsions were then transferred to 125 ml of an 
aqueous PVA solution (0.1% (w/v), Mw 30-70 KDa) and stirred at 600 rpm. A vacuum was 
applied to the aqueous phase for 2.5 hours to evaporate the methylene chloride and harden the 
microspheres. The hardened microspheres were transferred to 50 mL centrifuge tubes and 
collected via centrifugation at 1500 rpm for 2 minutes. The microspheres were then washed 
thrice with deionized water (10 mL each time), collected using the same centrifugation procedure 
as before and dried using a freeze dryer. The prepared microspheres were stored at 4°C until 
further use. 
5.2.2.2 Characterization of PLGA microspheres 
The microspheres were characterized for drug loading, glass transition temperatures and 
morphology. The drug loading was evaluated by dissolving approximately 5 mg of microspheres 
in 10 mL THF and analyzed using HPLC. Briefly, the solution was filtered (Millex® HV, PTFE 
0.45 μm syringe filter) and 5 μl samples were injected into the HPLC column. A Perkin Elmer 
series 200 HPLC system (Shelton, CT) equipped with a UV absorbance detector (240 nm wave 
length for dexamethasone analysis) was used. Acetonitrile/water/phosphoric acid (35/70/0.5, 
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v/v/v) was used as the mobile phase. A Zobax C18 (4.6 mm × 15 cm, Agilent, Santa Clara, CA) 
analytical column was used with a flow rate of 1 ml/min. The chromatographs were analyzed by 
PeakSimple™ Chromatography System (SRI instruments, Torrance, CA).   A TA Q1000 
differential scanning calorimeter (DSC) (TA, New Castle, DE) was used to determine the glass 
transition temperature (Tg) of the prepared microspheres. Modulated DSC was performed with 
the following cycle: the samples were heated at a rate of 3 °C/min from 4°C to 80 °C at a 
modulating oscillatory frequency of 1°C/min. The thermograms were analyzed using Universal 
Analysis software (TA Instruments) to determine the glass transition temperature. The 
morphology of the microspheres was determined using a scanning electron microscopy (a FEI 
Nova NanoSEM 450 unit). Samples were mounted on carbon taped aluminum stubs and sputter 
coated with gold for 1.5 min at 6 mA before imaging.  
5.2.2.3 PVA hydrogel composite coatings 
The PLGA microsphere/PVA hydrogel composites were prepared using a previously developed 
freeze-thaw method. Different amounts of PLGA microspheres (0, 50, 75, and 100 mg) were 
dispersed in 1 mL 5% (w/w) PVA solutions (133 KDa) and the dispersions were filled into 1-mL 
syringes (BD precision glide). Three freeze–thaw cycles (2 hour at - 20 °C and 1 hour at ambient 
temperature for each cycle) were applied to the suspension to form the crosslinked PVA 
hydrogels with PLGA microspheres embedded. The crosslinked composites were then removed 
from the syringes, air dried and stored in 4 ˚C for further use.  
5.2.2.4 Coating of microdialysis probes 
CMA20 microdialysis probes (Harvard Apparatus, Holliston, MA) with 20,000 molecular weight 
cutoff, 10 mm polyethersulfone (PES) membranes, were used for microdialysis testing. For 
coating the probes, the microspheres were dispersed in 5% (w/w) PVA solution (133 KDa) and 
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one freeze-thaw cycle was applied to the dispersion to thicken the gel before coating the 
microdialysis probes. Teflon tubing (0.047 inch inner diameter) was used to provide a cylindrical 
mold for coating. Using a syringe, the thickened gel solution was quickly dispensed into the 
tubing. The microdialysis probe tips (0.5 mm diameter) were inserted in the tubing and 2 
additional freeze-thaw cycles were applied. The tubing was removed from the hydrogel-coated 
microdialysis probes and the coatings were allowed to be air dried and stored in 4 ˚C for further 
use. Microdialysis probes coated with PVA hydrogel only were prepared using the same method 
except that microspheres were not added into the PVA solution. 
5.2.2.5 In vitro release testing  
In vitro release testing was performed for the PLGA microsphere/PVA hydrogel (99% 
hydrolyzed, Mw 133 KD) composite coatings. Approximately 2 mg of each formulation was 
immersed in a 2 ml Eppendorf vial containing 1.8 ml of 10 mM PBS (pH 7.4) with 0.1% NaN3 
and incubated at 37 °C under constant agitation. At pre-determined time points, all the release 
media was removed and replenished with fresh media. Sink conditions were maintained 
throughout. The samples were filtered through 0.45 μm syringe filters and the concentration of 
dexamethasone in each sample was determined using the HPLC method as described above.  
5.2.2.6 Swelling of composite coatings 
The swelling characteristics of the composite coatings were obtained by measuring their initial 
and swollen weights in phosphate buffered solution (10 mM, pH 7.4, PBS). Approximately 5 mg 
of completely dried samples were weighed (Wd) and immersed into 1.8 mL PBS solutions 
incubated at 37 ˚C.  At predetermined time points, the samples were then weighed again to 
obtain the swollen weight (Ws (t)) after being removed from the solutions and carefully dried 
 108 
 
using kimwipes to absorb any surface water. The degree of swelling was calculated as the 
swelling ratio using the equation below. 
𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑅𝑎𝑡𝑖𝑜 =
𝑊𝑠(𝑡) − 𝑊𝑑
𝑊𝑑
 
where Wd is the initial weight of dried coating and Ws(t) is the weight of swollen coating 
measured at the specified incubation time interval (t).  
5.2.2.7 Glucose diffusion through composite coatings 
All the microdialysis probes (without coating, with PVA coatings, with PVA/PLGA composite 
coatings) were incubated in the Franz cell apparatus with 5 mL PBS maintained at 37 °C for 3 
hours prior to the experiments to ensure complete hydration of the coatings. The probes were 
then connected to a syringe pump equipped with a 3-mL syringe filled with PBS. The pumping 
rate was set at 5 µL/min. After a 30 min equilibration period, 2 mL of 6 mg/mL glucose solution 
was added into the Franz cells and the perfusion fluid was collected every 6 mins for 30 min. 
The same test was repeated at pre-determined time points and the microdialysis probes were 
incubated in PBS maintained at 37 °C between each test. The glucose concentration in the outlet 
dialysate (Cd) and medium external to the dialysis probe (Ce) were measured using a YSI 2300 
Stat Plus Glucose & Lactate analyzer (YSI Inc., Yellow Spring, Ohio).  The permeability was 
determined as relative recovery (RR), which was calculated using the following equation:  
𝑅𝑅 =
𝐶𝑑(𝑡)
𝐶𝑒(𝑡)
 
where Cd(t) is the glucose concentration in the dialysate and Ce(t) is the glucose concentration in 
the medium external to the dialysis probe at the specified time points (t). 
5.2.2.8 Low temperature scanning electron microscopy (cryo-SEM) 
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In order to investigate the internal structure change of composite coatings, cryo-SEM was 
performed to evaluate the samples after incubation in PBS at 37 ˚C after specified time points. 
Samples of ~ 1 mm3 size were mounted onto standard specimen carriers (for the EM VCT100 
16BU012098-T holder, Leica Microsystems) surrounded by buffer, and plunge-frozen in liquid 
nitrogen slush. The samples were freeze-fractured at -140 °C, etched for 2 min at -95°C, and 
sputter coated with 7 nm thickness of platinum in the cryo-SEM sample prep station (EM MED 
020, Leica Microsystems). Samples were then transferred under vacuum to the FEG-SEM (Nova 
NanoSEM 450, FEI) and imaged at -140 °C (EM VCT100 cryo shuttle and cryo stage, Leica 
Microsystems). 
5.3 Results  
5.3.1 Characterization of PLGA microspheres 
Two types of microspheres were prepared using different polymers as shown in Table 1. DLG1A 
polymer has lower intrinsic viscosity and is more hydrophilic. The Tg of DLG1A microspheres 
was approximately 43.3 ˚C and had a molecular weight of approximately 7 kDa. RG503H has 
higher intrinsic viscosity and is more hydrophobic. The molecular weight of this polymer is 
approximately 25 kDa which is higher than that of DLG1A, leading to a higher Tg of 
approximately 48.2 ˚C. The Similar drug loading was obtained for both microsphere 
formulations, around 7.6% (w/w). 
Table 1 Physicochemical properties of the PLGA microsphere formulations  
Formulation Polymer type Polymer intrinsic 
viscosity (dl/g) * 
Tg 
(˚C) 
Drug loading 
(w/w) 
I     5050DLG1A ~0.08 43.3 7.72 ± 0.33% 
 II 5050RG503H  ~ 0.4 48.2 7.63 ± 0.28 % 
* Information provided in Analytical Report from Lakeshore Biomaterials 
Microsphere morphology was evaluated using SEM (Figure 5.1). Both formulations presented 
spherical shaped particles. Some irregular shaped particles were observed on the surface of the 
DLG1A (low MW) formulations while the surface of microspheres prepared using the RG503H 
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(high MW) was smooth. These particles are considered to be crystalline dexamethasone, which 
was not encapsulated inside the microspheres. The crystalline nature of these particles was 
confirmed using polarized light microscopy (data not shown). Surface dexamethasone may lead 
to higher drug burst release from this formulation. 
5.3.2 In vitro drug release from composite coatings 
Release profiles were obtained for composite coatings prepared using the two microsphere 
formulations (Figure 5.2). DLG1A based composite coatings exhibited a burst release of 
approximately 50% at 3 hours, more than 70% of the dexamethasone was released within 24 
hours, and drug release was complete within 10 days. For composite coatings prepared using 
RG503H based microspheres, three release phases were observed including an initial burst 
release phase, followed by a lag phase with minimal drug release and a secondary zero-order 
release phase. Approximately 35% of the drug was released during the burst phase within 24 
hours. The lag phase lasted for approximately 9 days and the drug release plateaued at 
approximately 1 month with more than 90% of the loaded drug released.  
5.3.3 Swelling of composite coatings 
Swelling properties of the composite coatings prepared with RG503H (high MW) microspheres 
are shown in Figure 5.3. The weight change of the samples is plotted in Figure 5.3-A. There was 
significant swelling within first few hours. After the initial swelling on the first day, the coatings 
without microspheres retained similar weight throughout the 45-day testing period. For the 
coatings with embedded microspheres, following the initial 1-day swelling period the coating 
weight was maintained for approximately 6 days following which the weight increased 
significantly until approximately day 24 and then decreased. From the swelling ratio plot shown 
in Figure 5.3-B, the composite coatings gained approximately 60% to 100% of their initial 
weight while the PVA hydrogel alone (no microspheres) gained more than 170% of the initial 
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weight during the first 24 hours. A negative correlation with the amount of microspheres 
embedded in the hydrogel was observed during the first 24 hours. While the swelling ratio of the 
PVA hydrogel alone was maintained at around 170% for 45 days, the swelling ratio of composite 
coatings increased starting from day 9 and reached a maximum after approximately 24 days. The 
maximum swelling ratio for the composite coatings ranged from 220% to 280% with a positive 
correlation with the amount of microspheres embedded.  
The swelling properties of the composite coatings prepared with DLG1A microspheres (low 
MW) are shown in Figure 5.4. The coatings loaded with the DLG1A microspheres continued to 
gain weight after incubation and reached a maximum at around 13 days. After day 13, the weight 
started to decrease during the testing period. As was the case for the coatings loaded with 
RG503H microspheres, these composite coatings gained approximately 60% to 100% of their 
initial weight within the first 24 hours. The maximum swelling ratio of these formulations 
occurred at day 13 and ranged from approximately 200% to 250% for the various microsphere 
concentrations. A positive correlation between the maximum swelling ratio and the concentration 
of microspheres embedded in the coating was observed.  
5.3.4 Glucose diffusion through composite coatings 
RR of glucose from the microdialysis probes is an indication of glucose permeability through 
various coatings (as shown in Figure 5.5). The RR of glucose through uncoated microdialysis 
probes and PVA hydrogel coated probes were maintained at approximately 37% and 21%, 
respectively over the testing period. When coatings containing embedded microspheres 
(prepared with the RG503H polymer) were applied to the probes, the RR decreased with increase 
in the microsphere concentration. For those coatings loaded with PLGA microspheres, the RR 
decreased initially following incubation and reached a minimum at approximately 24 days and 
 112 
 
then started to increase. The lowest RR (~5%) was observed for the 100 mg MS/ml PVA 
formulation at day 24. 
In order to further investigate the effect of microsphere swelling and degradation on glucose 
diffusion through the composite coating, glucose RR was also tested for coatings prepared using 
DLG1A microspheres (MS) following different incubation periods. Similar results to those for 
the coatings embedded with the RG503H microspheres were obtained, except that the time scale 
was faster, as shown in Figure 5.6. The RR decreased initially after incubation and reached the 
lowest point (~5%) at day 16 before it started to increase. When compared to the RR obtained for 
the composite coatings prepared using the RG503H microspheres, the initial RR decrease for the 
composites prepared with the DLG1A formulation was more abrupt and the minimum RR was 
reached earlier (approximately 16 days compared to 24 days). 
5.3.5 Internal pore formation  
Composite swelling and glucose diffusion characteristic changes are associated with internal 
structural change in the coatings. Cryo-SEM was performed on DLG1A microsphere based 
composite coatings after incubation for different time periods. Figure 7 shows the internal 
structure of the composite coatings following 2-h, 1-day, 3 days and 7 days. Two distinct layers, 
an external layer with small pores and an internal layer without pores, were observed in the 
microspheres following 2 hours of incubation (Figure 5.7-A2). From the highest magnification 
(~26000X) image (Figure 5.7-A3), it was determined qualitatively that the pores formed at 2 
hours are similar in size to the pores of the PVA hydrogel matrix. Interestingly, a transitional 
phase was observed between the microspheres and the PVA hydrogel indicating some possible 
interaction between the two phases (Figure 5.7-A2). Following 24 hours incubation, pores were 
observed throughout these microspheres (Figure 5.7-B2) and the pore size increased with time 
(comparing Figure 5.7-B3 with Figure 5.7-A3). After 3 and 7 days of incubation, increase in 
particle size was observed in the low magnification images (comparing Figure 5.7-C1, 5.7-D1 to 
Figure 5.7-A1). It can be observed from the high magnification images that the size of the 
internal pores continued to increase (Figure 5.7-C3, 5.8-D3). The transitional phase between the 
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microspheres and the hydrogel disappeared in the later time points (Figure 5.7-C3, 5.8-D3). It is 
also worth noting that these microspheres rapidly lost their spherical shape even after 2 hours of 
incubation. During the whole incubation period, no significant changes were observed in the 
PVA hydrogel structure other than the transitional phase.  
Cryo-SEM was also performed on PLGA microsphere/PVA hydrogel composites prepared using 
the RG503H polymer (Figure 5.8). Pores started to present close to the surface of the 
microspheres following 5 hours incubation. The pores grew in a pattern from the outside to the 
inside with small pores located close to the exterior and larger pores in the center of the 
microspheres. By day 6, the interior of the microspheres was filled with pores. The pore size 
increased from day 6 to day 9 (from approximately 240±138 nm to approximately 367±197 nm). 
Minor internal structure deformation was observed at day 9 (Figure 5.8-F). Starting from day 12, 
internal structure collapse was observed from the interior to the exterior as shown in Figures 5.8-
G and 5.8-H. Microsphere particle size was analyzed and the particle size increased significantly 
from day 6 to day 15 (Figure 5.8-I), which coincides with the swelling ratio change shown in 
Figure 5.3. The transitional layer between the microspheres and the PVA hydrogel was also 
observed for this formulation as shown in Figures 5.8-A and 5.8-B. It is worth noting that these 
microspheres maintained their spherical shape until day 6 following which shape changes were 
observed. 
5.4 Discussion 
5.4.1 Amount of microsphere water uptake during swelling 
PVA hydrogels have been widely used as biocompatible materials[31]. The short term swelling 
property of these hydrogels has been thoroughly investigated [32, 33]. They usually reach 
swelling equilibrium within a few hours which is consistent with the results reported here for the 
hydrogels alone and those loaded with the RG503H microspheres (Figure 5.3). In the case of the 
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hydrogels containing the DLG1A microspheres, a fast hydrogel equilibration period was not 
observed and this is probably due to masking by the rapid swelling of these microspheres. 
The long-term swelling properties of the PLGA microsphere/PVA hydrogel composites has not 
been previously reported. A positively correlated microsphere concentration dependent long-
term swelling pattern indicates that the microspheres were absorbing significant amounts of 
water. The onset of microsphere swelling coincides with the onset of the second drug release 
phase of RG503H microspheres and persisted during the remainder of the drug release period. 
Although a significant particle size change has been reported for PLGA microspheres at the 
onset of the second rapid drug release phase, the water uptake was not quantified in this study 
[14]. In the current study, we were able to quantify the amount of water uptake by the 
microspheres as they were embedded in the PVA hydrogels and the hydrogels only absorbed 
water during the initial fast equilibrium phase. The approximate maximum amount of water 
taken up by the microspheres was calculated using the equation below: 
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑅𝑎𝑡𝑖𝑜𝑀𝑆 =
𝑊𝑠(𝑡𝑚𝑎𝑥) − 𝑊𝑠(3)
𝑊𝑑 × (𝐶𝑀𝑆 ÷ (𝐶𝑀𝑆 + 50))
 
where Wd is the initial weight of the dry coating and Ws(tmax) is the weight of the swollen coating 
measured at the maximum swelling time (t), Ws(3) is the weight of the swollen coating following 
3 hours incubation, CMS is the amount (mg) of microspheres in one mL of 5% (w/w) PVA 
solution.  
For both microspheres, the maximum amount of water uptake ranges from 2 to 3 times their 
weight (Table 5.2).  
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Table 2 Calculated maximum swelling ratio of microspheres embedded in the composite 
coatings according to Figures 3 and 4 
Microsphere 
Concentration 
50 mg/mL PVA 75 mg/mL PVA 100 mg/mL PVA 
DLG1A MS 2.49 ± 0.03 2.33 ± 0.27 2.62 ± 0.12 
RG503H MS 2.15 ± 0.18 2.55 ± 0.11 2.97 ± 0.12 
 
5.4.2 Drug release mechanism from microspheres 
Different release profiles were observed for the composites prepared with the two different 
microsphere formulations (Figure 5.2). The high burst release observed for the DLG1A 
microsphere/PVA hydrogel composites is consistent with the low PLGA molecular weight, the 
hydrophilicity of these microspheres and the observation of surface associated dexamethasone 
(SEM images in Figure 5.1). In contrast, dexamethasone release from the RG503H formulation 
followed the typical tri-phasic PLGA microsphere release profile. The burst release, duration of 
the lag phase and the period for complete drug release is very similar to previously reported 
results obtained for RG503H PLGA microsphere/PVA hydrogel composites [20]. The tri-phasic 
release profile indicates that the RG503H microspheres follow a bulk erosion mechanism.  
The burst release of drug from microspheres is usually considered to be a result of surface drug 
diffusion. From our cryo-SEM results, the formation of transitional layers in the PVA hydrogel 
at early time points (Figures 5.7-A2, 5.8-A and 5.8-B) may be due to large amounts of drug 
diffusing out of the microspheres and disturbing the intrinsic gel structure during the burst 
release phase. The coincidence between the drug release profile and water uptake for both 
microsphere formulations indicates swelling as a possible contributing factor to drug release 
from both formulations. Increased osmotic pressure due to accumulation of degradation products 
as well as polymer matrix plasticization have been suggested as contributing factors to 
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microsphere swelling [14]. From the current investigation, the internal structure changes (i.e. 
development of a pore structure) also play a significant role affecting microsphere swelling. The 
onset of microsphere swelling was shown to correlate with the development of an internal porous 
structure for both types microspheres investigated (day 1 and day 6 for DLG1A and RG503H, 
respectively). During the lag phase, the following sequence of events occurs: 1) pores build up 
internally until the entire microsphere structure is porous, 2) the microspheres swell following 
pore formation, and 3) the significant influx of water leads to internal structure deformation 
followed by the onset of the second drug release phase. For hydrophobic drugs, the microspheres 
form a natural “osmotic pump” to maintain osmotic pressure from two aspects: 1) the internal 
microsphere space is filled with saturated drug solution providing consistent osmotic pressure; 2) 
osmotic pressure contributed by degraded oligomers and monomers is compromised from the 
microsphere swelling, and accordingly the second drug release phase is pseudo zero order. The 
surface layer of the microspheres remained intact during the drug release phase. This may be the 
reason that the microspheres continued to swell during the entire drug release phase.  
For both microsphere formulations, small pores formed early close to the exterior and large pores 
formed later within the microspheres. This pattern can be explained by a local pH gradient from 
the interior (high acidity) to the surface (low acidity) and the water diffusion kinetics into the 
microspheres. As the microspheres are in contact with the aqueous phase, water diffusion into 
the microspheres can result in a concentration gradient of drug and acidic degradation species. 
The surface layer of the microspheres is exposed to water earlier and therefore starts to degrade 
faster. However, the acidic degradation products do not build up close to the surface and 
therefore large pores do not form in this region. In contrast, the microsphere cores are exposed to 
water later compared to the surface and consequently pore formation occurs slower. However, 
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due to the pH effect from the accumulated acidic degradation products, those pores tend to grow 
large quickly. The pore morphology is interesting in that the larger pores are spherical in shape 
indicating that they are not formed as a result of connecting with neighboring pores. The uniform 
wall thickness between neighboring pores may originate from less viscous acid terminated 
PLGA oligomers that prefer to segregate their carboxyl ends toward pore surface. 
5.4.3 Effect of swelling on glucose diffusion 
Glucose diffusion through the composite coatings is another important characteristic with respect 
to their application as a coating for glucose biosensors. Glucose diffusion through the composite 
coatings is affected by the hydrophilicity and porosity of the coatings. When coated with the 
composites, microdialysis probes can provide insight into coating permeability to a specific 
analyte (i.e. glucose) in the form of RR. Employing the steady-state mass balance theory, a 
model has been proposed by Bungay et al. attributing RR to the perfusate flow rate (Qd) and a 
series of mass transport resistances [34]. The correlation is presented using the equation below: 
𝑅𝑅 = 1 − exp (−
1
𝑄𝑑 × (𝑅𝑑+𝑅𝑧 + 𝑅𝑒)
) 
where Rd, Rz, and Re are transport resistances of the dialysate, dialysis membrane, and external 
medium, respectively. Under well stirred conditions, the external medium resistance (Re) can be 
considered as zero. Norton, et al further separated Rz into the resistance contributed by the 
dialysis membrane (Rm), and that contributed by the hydrogel coating (Rh) using the equation 
below [35]. 
𝑅𝑧 = 𝑅𝑚 + 𝑅ℎ 
Rh can be further defined using the following equation: 
𝑅ℎ =
ln (𝑟ℎ/𝑟𝑜)
2𝜋𝐿𝐷ℎ𝜑ℎ
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where ro is the outer radius of dialysis probe, rh is the outer radius of the coating, L is the length 
of the microdialysis membrane, Dh is the glucose diffusion coefficient in the coating and φh is the 
fraction of glucose in the coating. Therefore, the apparent RR should be negatively related to the 
thickness of the coating (affecting rh) and positively related to the glucose diffusion coefficient 
(Dh) in the coating. 
In the current study, a positive correlation was observed using a plot between the RR and 
swelling ratio at 3 hours while a negative correlation was observed at maximum swelling date 
(day 24) for coatings prepared with RG503H microspheres (Figure 5.9). For coatings prepared 
using DLG1A microspheres, although the positive correlation at 3 hours was not observed due to 
the masking effect from microsphere swelling, at maximum swelling date (day 13), such pattern 
of negative correlation was also observed. The positive correlation at 3 hours can be attributed to 
a negative dependence of water uptake into the PVA hydrogel on the microsphere concentration 
(prepared using the RG503H polymer). During this initial phase, more glucose mobility (increase 
of Dh) is expected with increase in the hydrophilicity of the coating. Further swelling of the 
coating was observed and water uptake reached a maximum at day 24. As the majority of the 
coating is composed of water by this time point, the effect of the coating thickness change 
(change of rh) dominates the contribution to RR leading to a negative correlation between 
swelling and RR. Glucose diffusion through the microsphere is limited as the microsphere shell 
was observed throughout the drug release phase (shown in Figure 5.8) in addition to the high 
internal osmotic pressure. However, the increase of RR post the second drug release phase can 
possibly be explained by the disappearance of the microsphere shell and therefore glucose is able 
to freely pass through the holes that were earlier occupied by the microspheres. In addition, 
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decrease in water uptake was observed post the second drug release phase indicating that the 
coating was shrinking (decreasing in thickness) with the disappearance of the microsphere shells.  
5.5 Conclusion 
The present study demonstrated new insights into PGLA microsphere drug release mechanisms 
through investigation of swelling, internal pore formation and glucose diffusion for two types of 
PLGA microspheres (with and without lag phase) embedded in PVA hydrogels. For the first 
time, detailed internal structure of PLGA microspheres during drug release was revealed with the 
assistance of cryo-SEM. The results suggest that both types of microspheres undergo 
heterogeneous erosion, and swelling. The outside-in pattern of porosity progression in the 
microspheres explains the lag phase observed in some PLGA microsphere products. The length 
of the lag phase is determined by the time required for the entire microsphere to become porous 
which is controlled by the molecular weight and hydrophobicity of the polymer. The onset of 
drug release post the lag phase appears to be a consequence of microsphere swelling following 
pore formation. Continuous microsphere swelling during the second drug release phase may also 
affect the drug release kinetics. In addition, the timing and amount of water absorption measured 
during the swelling process will be useful for researchers who are interested in building 
mechanistic mathematical models depicting drug release from microspheres. This information 
can be used by researchers to develop microspheres with specific release patterns for different 
applications. The information generated in this study on the dynamic internal changes in the 
microspheres will also be useful in understanding drug stability during the release process. 
Furthermore, the correlation between microsphere swelling and glucose permeation through the 
coatings will facilitate coating design for glucose sensors and other similar implantable devices. 
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5.6  Tables and Figures 
Table 5.1 Physicochemical properties of the PLGA microsphere formulations  
Formulation Polymer type Polymer intrinsic 
viscosity (dl/g) * 
Tg 
(˚C) 
Drug loading 
(w/w) 
I     5050DLG1A ~0.08 43.3 7.72 ± 0.33% 
 II 5050RG503H  ~ 0.4 48.2 7.63 ± 0.28 % 
* Information provided in Analytical Report from Lakeshore Biomaterials 
 
 
 
Table 5.2 Calculated maximum swelling ratio of microspheres embedded in the composite 
coatings according to Figures 5.3 and 5.4 
Microsphere 
Concentration 
50 mg/mL PVA 75 mg/mL PVA 100 mg/mL PVA 
DLG1A MS 2.49 ± 0.03 2.33 ± 0.27 2.62 ± 0.12 
RG503H MS 2.15 ± 0.18 2.55 ± 0.11 2.97 ± 0.12 
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Figure 5.1. SEM images of PLGA microspheres prepared using DLG1A (A) and RG503H (B)  
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Figure 5.2. In vitro release profiles of composite coatings prepared using DLG1A (A) and 
RG503H (B) based microspheres 
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Figure 5.3. Swelling of PLGA microsphere/PVA hydrogel composite coatings prepared using 
RG503H based microspheres. The weight change of the samples is shown in A (n=3) and the 
swelling ratio change is shown in B (n=3). The data is presented as average ± SD for the 
swelling ratio.  
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Figure 5.4. Swelling of PLGA microsphere/PVA hydrogel composite coatings prepared using 
DLG1A based microspheres. The weight change of the samples is shown in 4 (n=3) and swelling 
ratio change is shown in 4 (n=3). The data is presented as average ± SD for the swelling ratio.  
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Figure 5.5. Effect of different types of coating and incubation time on glucose relative recovery 
obtained using microdialysis probes (n=3 for each time point). Microspheres used were prepared 
using the RG503H polymer. 
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Figure 5.6. Glucose relative recovery from composite coatings embedded with microspheres 
(100 mg MS/ml PVA) prepared using RG503H and DLG1A polymers 
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Figure 5.7. Cryo-SEM images showing the internal structure of the PLGA microsphere/PVA 
hydrogel composites (prepared using DLG1A polymer) after incubation in phosphate buffer for 2 
hours (A1, A2, A3), 1 day (B1, B2, B3), 3 days (C1, C2, C3) and 7 days (D1, D2, D3). Images 
are provided at low magnification (A1, B1, C1, D1), medium magnification (A2, B2, C2, D2) 
and high magnification (A3, B3, C3, D3). Red arrows point at the microspheres at low 
magnification, red triangles point at the microspheres at medium/high magnification, green 
squares point at the hydrogel at medium/high magnification and white arrows point at the 
interphase between the microsphere and the PVA hydrogel. 
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Figure 5.8. Cryo-SEM images showing the internal structure of the PLGA microsphere/PVA 
hydrogel composites (prepared using the RG503H polymer) following incubation in phosphate 
buffer for 3h, 5h, 1 day, 2 days, 4 days, 9 days, 12 days and 15 days (corresponding to A, B, C, 
D, E, F, G, H, respectively). The red triangles point at the microspheres, the green squares point 
at the hydrogel, the white arrows point at the interphase between microsphere and PVA 
hydrogel, and the yellow arrows point at the deformation/collapse of the porous structure. I 
shows particle size change over time obtained by analyzing low magnification images 
(approximately 1000X, data not shown) following 5h, 6 day and 15 day incubation. 
Approximately 100 particles were analyzed for each image.* indicates statistical significance 
analyzed using paired student t-test (p<0.001) 
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Figure 5.9. Correlation between coating swelling ratio and RR of glucose through the coatings 
prepared with RG503H microspheres following 3 hours (A) and 24 days (B) incubation.  
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Chapter 6  
 
Conclusions and Future Studies 
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6.1. Summary and conclusions 
Continuous glucose monitoring using implantable glucose sensors will significantly improve the 
quality of life for diabetic patients. There are currently several semi-implantable glucose sensors 
available on the market. However, these sensors suffer from short life-time of approximately 7 
days which limits their application. The sensors lose functionality rapidly due to a series of 
immune reactions including acute inflammation, chronic inflammation and fibrous 
encapsulation. PLGA microsphere/PVA hydrogel composites have been developed to act as 
biocompatible coatings for implantable glucose sensors to increase sensor life-time and enhance 
sensor performance. The sensor life-time can be extended with the continuous release of anti-
inflammatory drug (i.e. dexamethasone) to counter those reactions and the duration of drug 
release has a significant impact on sensor life-time. The sensor performance is related to glucose 
diffusion through the coating and therefore is related to the microscopic dynamic changes (i.e. 
hydrophilicity and porosity) in the coating during drug release. Accordingly, the main scope of 
this work was to develop a coating to maximize sensor life-time through long-term (6 months) 
drug release, and understanding of dynamic changes in the coating.  
Blending different PLGA polymers for microsphere manufacturing was shown to be an 
effective strategy modulating drug release properties. The low Mw PLGA increases water 
absorption into the polymer matrix and generates acidic oligomers/monomers which facilitate the 
autocatalysis of the high Mw polymer resulting in a smoother release profile. A polymer blend 
based dexamethasone microsphere/hydrogel formulation with continuous drug release and in 
vivo efficacy of 4.5 months was achieved in a preliminary testing. The composition of the 
polymer blends is critical to the release profile. One formulation blending the low and high Mw 
polymer at a 50:50 ratio exhibited high burst and short duration of drug release due to polymer 
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phase separation during the microsphere formation process. In addition, accelerated drug release 
methods were developed under elevated temperature conditions to significantly shorten the 
testing period from months to days while retaining the ability to discriminate among the various 
formulations. The discriminatory accelerated testing method can be used to evaluate long-term 
drug releasing coatings in the future for quality control purposes. 
Further optimization of the composition was achieved following a DoE approach using a 
central composite design. A design space with appropriate formulation outcomes (e.g. high drug 
loading and low burst release) was obtained based on the developed highly predictive DoE 
models. The optimized design space was shown to be valuable in predicting and controlling both 
burst release and drug loading, and it can serve as a blueprint to design PLGA blend based 
microsphere formulations with defined release attributes. According to the design space, 
approximately 85 mg of dexamethasone and 85% of high molecular weight PLGA were required 
in order to achieve a formulation with approximately 15% (w/w) dexamethasone loading and 
10% (w/w) burst release. In addition, a fundamental understanding of the effect of microsphere 
composition on the formulation performance was obtained by examining the formulation particle 
size, thermal properties as well as morphologies. Importantly, a novel heat map describing the 
daily drug release was developed to differentiate the various formulations during the lag phase 
where there is low/no drug release. Drug release properties are usually described using release 
profiles which may not be sufficiently detailed to describe the lag phase. In contrast, the drug 
release lag phase was illustrated clearly via the heat map and comparison between various 
formulations was easily made. Such heat maps are especially helpful for researchers who need to 
screen the release properties of a large number of formulations. 
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The optimized microsphere formulation was shown to continuously release 
dexamethasone at a sufficient dose to inhibit the FBR for 6 months. Further mixing the 
optimized microspheres with a single polymer based formulation demonstrated in vitro drug 
release of more 7 months, achieving the longest dexamethasone releasing formulation reported 
by far. Meanwhile, the heat map obtained using the formulations evaluated in vivo suggested that 
the minimum dexamethasone daily dose required to suppress chronicle inflammation is 
approximately 0.1 µg/mg of implant in rats, which can provide guidance for future coating 
design of glucose sensors. The heat map can potentially serve as a useful tool for establishing a 
clinically relevant dose of such long-term drug release formulations. The successful development 
of a long-term effective composite coating paves the way for the realization of long-term, totally 
implantable continuous glucose monitoring systems. 
Lastly, new insights into PGLA microsphere drug release mechanisms was obtained from 
the investigation of swelling, internal pore formation and glucose transport for two types of 
PLGA microspheres (with and without lag phase) embedded in PVA hydrogels. Detailed internal 
structure of PLGA microspheres during drug release was revealed with the assistance of cryo-
SEM. The results suggest that both types of microspheres undergo heterogeneous erosion, and 
swelling. The outside-in pattern of porosity progression in the microspheres explains the lag 
phase observed in some PLGA microsphere products. The length of the lag phase is determined 
by the time required for the entire microsphere to become porous which is controlled by the 
molecular weight and hydrophobicity of the polymer. The onset of drug release post the lag 
phase appears to be a consequence of microsphere swelling following pore formation. 
Continuous microsphere swelling during the second drug release phase lead to an increase of 
coating thickness which negatively affected glucose diffusion. This correlation between 
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microsphere swelling and glucose permeation through the coatings will facilitate coating design 
for glucose sensors and other similar implantable devices in the future.  
 The significant and novel contributions resulting from this work include: i) expanding the 
application of PLGA polymers by proving that drug release properties from PLGA microspheres 
can be modulated via blending different types of PLGA polymers; ii) generating predictive 
models to achieve appropriate microsphere composition for desired release profiles; iii) 
developing accelerated drug release methods for such long-term drug release formulations; iv) 
establishing a novel method (i.e. a heat map of daily drug release in vitro) for depicting drug 
release from long-term drug release formulations; v) achieving a 6-month in vivo effective 
dexamethasone eluting coating for implantable glucose sensors; vi) determining the minimum 
dexamethasone dose required to suppress chronic inflammation in a rat model; vii) revealing the 
drug release mechanisms from PLGA microspheres embedded in PVA hydrogel coatings; viii) 
demonstrating the long-term effect of microsphere degradation on glucose transport through the 
composite coatings. In conclusion, the results of this research have advanced the implementation 
of PLGA microsphere/PVA hydrogel composites as a drug-eluting coatings for long-term 
functional glucose biosensors. This research also adds knowledge to the fundamental 
understanding of PLGA microspheres which can further their applications as drug delivery 
systems. 
6.2. Future studies 
The continuous drug release profile obtained from polymer blend based microspheres is 
composed of multiple distinct phases which are not a simple combination of the release profiles 
obtained from mixing two individual microspheres prepared each with one polymer. Further 
investigation into the drug release mechanism from these microspheres can be conducted by 
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evaluating changes in molecular weight, internal structure and pH distribution, as well as 
swelling properties. A more detailed physical state (phase separation and polymer miscibility) of 
blended PLGA in these microspheres can be evaluated using solid state NMR, small-angle X-ray 
scattering, and small-angle neutron scattering techniques. 
The current study demonstrated that the in vivo efficacy of the optimized formulation lasted 
for approximately 6 months, which approximately corresponds to the in vitro drug release 
duration from the coatings. Development of a detailed in vitro-in vivo correlation (IVIVC) can be 
an interesting future topic. In addition, it will be helpful to develop more detailed dose-response 
correlations during different inflammatory phases for sensors with different size/geometry. PVA 
hydrogels loaded with different amounts of free dexamethasone can be used to determine the 
dose required during the acute inflammation phase. During the chronic inflammation phase, with 
the assistance from the heat map, the effect of dexamethasone dose on specific immune reactions 
such as cytokine expression, macrophage polarization, timing of neutrophil recruitment and 
fibroblast activation can also be evaluated using immuno-histological staining and western blot 
analysis, etc. In addition, the dexamethasone dose obtained from animal studies should be 
carefully investigated to satisfy both efficacy and safety when transitioning the coating to clinical 
studies considering differences between species.  
So far, these long-term coatings have not been tested with functioning glucose sensors. It is 
possible that long-term dexamethasone release may suppress the growth of blood vessels near 
the sensor therefore affecting sensor response. Different types of coatings can be evaluated to 
promote angiogenesis including co-delivery of vascular growth factors (e.g. VEGF and PDGF) 
and changing the coating morphology (e.g. different degrees of porosity). 
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The dynamic changes within the PLGA microspheres embedded in the PVA hydrogel were 
revealed using CryoSEM. This technique may be further used to evaluate individual 
microspheres to explore how/when the microsphere swelling/internal pore formation takes place. 
The process of microsphere structure collapse may be different without the supporting of a PVA 
hydrogel. In addition, microdialysis was used in the study as a tool to evaluate the effect of the 
coating on in vitro glucose transport. Microdialysis can also be performed in vivo to determine 
the effect of different phases of the FBR on glucose transport.  
 
 
 
